- 1 Symptoms and SARS-CoV-2 positivity in the general population in the UK
- 2 Authors
- 3 Karina-Doris Vihta^{1,2,3*}, Koen B. Pouwels^{2,6}, Tim Peto^{1,2,4,5}, Emma Pritchard^{1,2}, David W. Eyre^{1,2,5,7},
- 4 Thomas House^{8,9}, Owen Gethings¹⁰, Ruth Studley¹⁰, Emma Rourke¹⁰, Duncan Cook¹⁰, Ian Diamond¹⁰,
- 5 Derrick Crook^{1,2,4,5}, Philippa C. Matthews^{1,5}#, Nicole Stoesser^{1,2,4,5}#, Ann Sarah Walker^{1,2,5}#, and the
- 6 COVID-19 Infection Survey team
- 7 # contribution considered equal
- 8 Affiliations
- 9 ¹ Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 10 ² The National Institute for Health Research Health Protection Research Unit in Healthcare Associated
- 11 Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
- 12 ³ Department of Engineering, University of Oxford, Oxford, UK
- ⁴ The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford,
- 14 Oxford, UK
- 15 ⁵ Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation
- 16 Trust, John Radcliffe Hospital, Oxford, UK
- ⁶ Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford,
- 18 Oxford, UK
- ⁷ Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- 20 ⁸ Department of Mathematics, University of Manchester, Manchester, UK
- ⁹ IBM Research, Hartree Centre, Sci-Tech Daresbury, UK
- 22 ¹⁰ Office for National Statistics, Newport, UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 See Acknowledgements for the Coronavirus Infection Survey team
- 24
- 25 Keywords: SARS-CoV-2, community, symptoms
- 26
- 27 Running title: Symptoms and SARS-CoV-2 positivity
- 28 Summary (38 words limit 40)
- 29 Within the COVID-19 Infection Survey, recruiting representative households across the UK general
- 30 population, SARS-CoV-2-associated symptoms varied by viral variant, vaccination status and
- 31 demographics. However, differences are modest and do not currently warrant large-scale changes to
- 32 targeted testing approaches.
- 33
- 34 Corresponding author: Karina-Doris Vihta, Institute of Biomedical Engineering, Department of
- 35 Engineering Science, University of Oxford, OX1 2JD, Oxford, U.K. Email karina-
- 36 <u>doris.vihta@eng.ox.ac.uk</u>. Tel: +44 7707931091.
- 37

38 ABSTRACT (250 words, limit 250 words)

Background: Several community-based studies have assessed the ability of different symptoms to
identify COVID-19 infections, but few have compared symptoms over time (reflecting SARS-CoV-2
variants) and by vaccination status.

42 Methods: Using data and samples collected by the COVID-19 Infection Survey at regular visits to

43 representative households across the UK, we compared symptoms in new PCR-positives and

44 comparator test-negative controls.

60

approaches given resource implications.

45 Results: From 26/4/2020-7/8/2021, 27,869 SARS-CoV-2 PCR-positive episodes occurred in 27,692 46 participants (median 42 years (IQR 22-58)); 13,427 (48%) self-reported symptoms ("symptomatic 47 positive episodes"). The comparator group comprised 3,806,692 test-negative visits (457,215 48 participants); 130,612 (3%) self-reported symptoms ("symptomatic negative visits"). Reporting of any 49 symptoms in positive episodes varied over calendar time, reflecting changes in prevalence of 50 variants, incidental changes (e.g. seasonal pathogens, schools re-opening) and vaccination roll-out. 51 There was a small increase in sore throat reporting in symptomatic positive episodes and negative 52 visits from April-2021. After May-2021 when Delta emerged there were substantial increases in 53 headache and fever in positives, but not in negatives. Although specific symptom reporting in 54 symptomatic positive episodes vs. negative visits varied by age, sex, and ethnicity, only small 55 improvements in symptom-based infection detection were obtained; e.g. adding fatigue/weakness 56 or all eight symptoms to the classic four symptoms (cough, fever, loss of taste/smell) increased 57 sensitivity from 74% to 81% to 90% but tests per positive from 4.6 to 5.3 to 8.7. Conclusions: Whilst SARS-CoV-2-associated symptoms vary by variant, vaccination status and 58 59 demographics, differences are modest and do not warrant large-scale changes to targeted testing

61 INTRODUCTION

62 Whilst a substantial proportion of individuals infected with SARS-CoV-2 remain asymptomatic[1,2], 63 symptoms are associated with higher viral loads[3], and higher viral loads with infectivity and 64 transmission[4]. Resource constraints generally prevent universal testing being deployed, so testing 65 and isolation strategies are usually targeted to those with symptoms most predictive of infection 66 and/or contacts of known positive individuals. Currently, four "classic" symptoms trigger PCR-based 67 community testing in the UK, namely: loss/change of smell/taste, fever, and/or a new, continuous cough. In the US, the Centers for Disease Control and Prevention (CDC) advises testing for any of 68 69 fever or chills, cough, shortness of breath/difficulty breathing, new loss of taste/smell, fatigue, 70 muscle or body aches, headache, sore throat, congestion/runny nose, nausea/vomiting, or diarrhoea. 71

72 As national testing policies depend on symptoms, understanding their predictive value in the context 73 of seasonality, changing prevalence of different variants[3], and widespread vaccination[5] is 74 essential. Most studies to date have restricted to those hospitalised or seeking healthcare, who do 75 not represent most infections[6]. Three recent UK community-based studies suggested that 76 sensitivity could be increased by 10-20% by extending the "classic" symptoms (REACT[7], adding 77 combinations of headache, muscle aches, chills and appetite loss depending on age; ZOE[8], adding different symptoms depending on age, sex, BMI and working in healthcare; VirusWatch[9], adding 78 79 feeling feverish, headache, muscle aches, loss of appetite or chills) but at a cost of increasing 80 numbers eligible for testing 2-3 fold and tests per positive identified up to 7-fold. However, these 81 studies were mainly before widespread vaccination, and whilst Alpha dominated. ZOE found no 82 evidence of difference in reported symptoms between wild type and the Alpha variant[10]. With 83 Delta, ZOE has recently identified headache, sore throat and runny nose/sneezing as non-classic 84 symptoms most commonly occurring in fully, partially and unvaccinated positives, respectively[11].

85

We therefore used a large community-based survey representative of the UK general population to investigate symptoms over time in PCR-positive episodes and negative controls, also evaluating the impact of age, ethnicity, cycle threshold (Ct) value, vaccination status and PCR gene profile (as a proxy for variant).

90

91 METHODS

- 92 The Office for National Statistics (ONS) COVID-19 Infection Survey[12] (ISRCTN21086382,
- 93 https://www.ndm.ox.ac.uk/covid-19/covid-19- infection-survey/protocol-and-information-sheets)
- 94 continuously randomly selects private households from address lists and previous surveys. Having
- 95 obtained verbal agreement, each household is visited by a study worker, and written informed
- 96 consent obtained for individuals aged $\geq 2y$ (from parents/carers for those 2-15y, with those 10-15y
- 97 also providing written assent). At the first visit, participants are asked for consent for optional follow-
- 98 up visits every week for the next month, then monthly thereafter. At each visit, participants provide
- 99 a nose and throat self-swab following instructions from the study worker and answer questions
- about behaviours, work, vaccination uptake and symptoms in the last 7 days
- 101 (https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/case-record-forms). Twelve specific
- symptoms are elicited, namely: loss of taste, loss of smell, fever, cough, headache,
- 103 tiredness/weakness (denoted fatigue/weakness), muscle ache (denoted muscle ache/myalgia),
- abdominal pain, diarrhoea, nausea or vomiting, shortness of breath and sore throat; plus a general
- 105 question about presence of symptoms participants considered COVID-19-related (denoted any
- 106 evidence of symptoms).

107

- 108 Swabs are tested at national testing laboratories using the Thermo Fisher TaqPath PCR assay (3
- 109 targets: ORF1ab, nucleocapsid (N), and spike protein (S)). If N and/or ORF1ab genes are detected,
- samples are called positive; the S-gene can accompany other genes, but does not count as positive
- alone (27/34,494 (0.08%) only S-gene positives counted as negative).

-1	1	ר
_		_

113	We included the first study positive test in each positive "episode", defining re-infections (arbitrarily)
114	as occurring \geq 120 days after an index positive with a preceding negative test, or after 4 consecutive
115	negative tests[5]. Each episode was classified by the minimum Ct value across positive tests in it and
116	as wild-type/Delta-compatible if the S-gene was ever detected within it (by definition, with
117	N/ORF1ab/both), otherwise Alpha-compatible if positive at least once for ORF1ab+N, otherwise
118	"other" (N-only/ORF1ab-only) (Fig.S1). Symptom presence included reports at any visit (test-
119	positive/negative/failed) within [0,+35] days of the first positive per episode (i.e. spanning [-7,+35]
120	days given the question timeframe).
121	
122	The comparator was visits with negative PCR tests, excluding visits with symptoms related to ongoing
122	The comparator was visits with negative rentests, excluding visits with symptoms related to ongoing
123	COVID-19 (and long COVID), with high probability of undetected COVID-19, and where symptoms
124	were likely driven by recent vaccination (details in Supplementary Methods).
125	
126	Statistical analyses
126 127	Statistical analyses Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms,
127	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms,
127 128	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted
127 128 129	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted "symptomatic positive episodes" and "symptomatic negative visits" respectively. We considered all
127 128 129 130	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted "symptomatic positive episodes" and "symptomatic negative visits" respectively. We considered all positive episodes, as well as subgroups defined by Ct (reflecting viral load), gene positivity pattern
127 128 129 130 131	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted "symptomatic positive episodes" and "symptomatic negative visits" respectively. We considered all positive episodes, as well as subgroups defined by Ct (reflecting viral load), gene positivity pattern (reflecting variant compatibility), vaccination status, age and calendar time (reflecting background
127 128 129 130 131 132	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted "symptomatic positive episodes" and "symptomatic negative visits" respectively. We considered all positive episodes, as well as subgroups defined by Ct (reflecting viral load), gene positivity pattern (reflecting variant compatibility), vaccination status, age and calendar time (reflecting background
127 128 129 130 131 132	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted "symptomatic positive episodes" and "symptomatic negative visits" respectively. We considered all positive episodes, as well as subgroups defined by Ct (reflecting viral load), gene positivity pattern (reflecting variant compatibility), vaccination status, age and calendar time (reflecting background
127 128 129 130 131 132 133	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted "symptomatic positive episodes" and "symptomatic negative visits" respectively. We considered all positive episodes, as well as subgroups defined by Ct (reflecting viral load), gene positivity pattern (reflecting variant compatibility), vaccination status, age and calendar time (reflecting background incidental symptoms) (details in Supplementary Methods).
127 128 129 130 131 132 133 134	Primary analyses restricted to positive episodes and negative visits with evidence of any symptoms, because this is the population targeted by public health messages to test and self-isolate, denoted "symptomatic positive episodes" and "symptomatic negative visits" respectively. We considered all positive episodes, as well as subgroups defined by Ct (reflecting viral load), gene positivity pattern (reflecting variant compatibility), vaccination status, age and calendar time (reflecting background incidental symptoms) (details in Supplementary Methods).

distribution with complementary log-log link, mgcv (v.1.8-31) package), adjusting simultaneously for

138 calendar time (smoothing spline), age (smoothing spline), sex, ethnicity (white vs non-white). We

139 tested whether effects varied by positive/negative episodes/visits using interaction tests. In positives

140 only, separate models also adjusted for Ct value (smoothing spline) and gene-positivity, or

141 vaccination status (details in Supplementary Methods).

142

- 143 We assessed the impact on performance of adding each of the other eight symptoms to the four
- 144 classic symptoms currently prompting testing in the UK, and of every combination of 1-8 symptoms,
- and any of the 12 elicited symptoms, using standard metrics (details in Supplementary Methods, epiR
- 146 (v.1.0-15), pROC (v.1.16.2) packages) plus tests per case (TPC)=1/positive predictive value (PPV) and
- 147 the inflation factor=episodes/visits with any included symptom/episodes/visits with classic
- symptoms. Finally, for each positive episode, we compared symptoms reported at the first vs
- subsequent visits within the episode (both absent, both present, absent then present, present then
- absent), and the associated Ct distributions.

151

152 RESULTS

- Between 26/4/2020-7/8/2021, 5,130,318 study PCR results were available from 484,317 participants;
- 154 34,494 (0.67%) were SARS-CoV-2-positive. In total, 27,869 positive episodes occurred in 27,692
- participants (median age 42 years (IQR 22-58)); 13,427 (48%) self-reported symptoms ("symptomatic
- positive episodes"). The comparator group comprised 3,806,692 negative visits (457,215 participants,
- 157 median age 52 years (IQR 32-66)); 130,612 (3%) self-reported symptoms ("symptomatic negative

158 visits") (exclusions in **Tables S1&S2**; characteristics in **Table S3**).

159

160 Specific symptoms are associated with SARS-CoV-2 and variants

161	Fatigue/weakness, cough, and headache were the most frequently reported symptoms in positive
162	episodes (54%, 54%, 52% of symptomatic positive episodes; Fig.1). However, headache and cough
163	were most frequently reported amongst negative visits too, together with sore throat (23%, 22%,
164	22%; Fig.1). Loss of taste/smell were the most specific symptoms for SARS-CoV-2 positivity (33%/33%
165	positive episodes, only 2%/2% negative visits). In positive episodes, loss of taste or smell were
166	commonly co-reported, as were gastrointestinal symptoms, and headache/myalgia/fatigue.
167	Symptom co-reporting in symptomatic positive episodes was generally similar regardless of Ct,
168	variant, vaccination status or age (Fig.S2), although myalgia was less strongly co-reported with
169	headache/fatigue in those 6-15y, with Delta and in those \geq 14d post-second vaccination. Patterns
170	were broadly similar in negatives, except cough and sore throat were more commonly co-reported.
171	
172	Symptomatology varied significantly by variant (Fig.1); with a smaller percentage of symptomatic
172 173	Symptomatology varied significantly by variant (Fig.1); with a smaller percentage of symptomatic positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type
173	positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type
173 174	positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type (38%/36%) or Delta-compatible (38%/39%) symptomatic positive episodes (p<0.0001).
173 174 175	positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type (38%/36%) or Delta-compatible (38%/39%) symptomatic positive episodes (p<0.0001). Fever/headache/sore throat had the largest difference between symptoms reported for Alpha-
173 174 175 176	positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type (38%/36%) or Delta-compatible (38%/39%) symptomatic positive episodes (p<0.0001). Fever/headache/sore throat had the largest difference between symptoms reported for Alpha- compatible (37%/56%/38%) and Delta-compatible (46%/62%/50%) symptomatic positive episodes
173 174 175 176 177	positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type (38%/36%) or Delta-compatible (38%/39%) symptomatic positive episodes (p<0.0001). Fever/headache/sore throat had the largest difference between symptoms reported for Alpha- compatible (37%/56%/38%) and Delta-compatible (46%/62%/50%) symptomatic positive episodes (p<0.0001). Cough and fatigue/weakness had the largest differences between wild-type (50%/50%)
173 174 175 176 177 178	positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type (38%/36%) or Delta-compatible (38%/39%) symptomatic positive episodes (p<0.0001). Fever/headache/sore throat had the largest difference between symptoms reported for Alpha- compatible (37%/56%/38%) and Delta-compatible (46%/62%/50%) symptomatic positive episodes (p<0.0001). Cough and fatigue/weakness had the largest differences between wild-type (50%/50%) vs Alpha-compatible (61%/61%) or Delta-compatible (64%/60%) symptomatic positive episodes

182 Symptomatology over calendar time

Adjusting for age, sex and ethnicity, the probability of symptoms being reported amongst positive
episodes was reasonably stable after August-2020 given changes in incidence and sample size (Fig.2,
top panels), with fluctuations likely reflecting school return in September-2020 and March-2021, plus

186 the emergence of Alpha and Delta in November-2020 and May-2021. Smaller fluctuations in 187 reporting any symptoms in negative visits (Fig.2, bottom panels) mirrored those in positive episodes. 188 The percentage of symptomatic positive episodes reporting each specific symptom generally 189 increased over time, consistent with increasing awareness. Reporting of most specific symptoms 190 except loss of taste/smell temporarily peaked in January-2021, consistent with the peak in Alpha, 191 then remained approximately constant through to May-2021, before increasing again, markedly so 192 for headache, cough and fever after Delta became dominant. Increases in cough and sore throat in 193 symptomatic negative visits occurred after school return in September-2020, in January-2021 when 194 schools were shut, and from early April-2021, consistent with other respiratory viruses. The winter 195 months saw particular increases in gastrointestinal symptoms, fatigue/weakness, myalgia and 196 headache in symptomatic negative visits, consistent with the presence of other common seasonal 197 pathogens.

198

199 Symptomatology by age, sex and ethnicity

200 All symptoms showed marked variation across age in both positive episodes and negative visits, 201 mostly being reported less in children and elderly adults (Fig.3). Loss of taste/smell were most 202 frequently reported in symptomatic positive episodes in those aged ~20y, decreasing gradually at 203 older ages; both were rarely reported amongst symptomatic negative visits, consistent with their 204 high specificity for SARS-CoV-2, although slightly more in the elderly. Sore throat and headache also 205 peaked in symptomatic positive episodes and negative visits in late adolescence, but were common 206 regardless of positivity. High proportions reported cough, relatively similarly amongst symptomatic 207 positive episodes and negative visits to \sim 10y, therefore without discriminating; however, above 20y 208 the proportion reporting cough was more than double in symptomatic positive episodes, and 209 increased to ~60y, as did fatigue/weakness, shortness of breath, and diarrhoea.

210

211 Adjusting for calendar time, age and ethnicity, women were generally more likely than men to report 212 most symptoms (Fig.4). Increased reporting in women was significantly greater in symptomatic 213 positive episodes than negative visits for loss of smell and taste, diarrhoea and shortness of breath, 214 and significantly smaller for headache and sore throat (all heterogeneity p<0.01). Whilst there was 215 no evidence of differential reporting of fever between male and female symptomatic negative visits, 216 female symptomatic positive episodes were significantly less likely to report fever (p<0.001). 217 218 After adjusting for calendar time, age and sex, in both symptomatic positive episodes and negative 219 visits, non-white ethnic groups were more likely to report fever than white ethnic groups, and less 220 likely to report headache, nausea/vomiting and shortness of breath (Fig.4). Those from non-white 221 ethnic groups were less likely to report loss of taste or smell and shortness of breath to a significantly 222 greater degree in symptomatic positive episodes versus negative visits (all p<0.01). 223 224 Symptoms by vaccination status 225 Both positive episodes and negative visits had lower odds of reporting any evidence of symptoms 226 compared to those pre-vaccination with no evidence of difference (p>0.44, Fig.5). However, positives 227 episodes \geq 21d from first vaccination had significantly lower odds of reporting 10/12 symptoms 228 compared to negative-visits (p<0.01).

229

230 Symptoms by Ct value in PCR-positive episodes

At low Ct values (≤20) (a proxy for high viral load), the most commonly reported symptoms were

232 cough, fatigue/weakness, headache and muscle ache/myalgia, all occurring in >50% of episodes

233 (Fig.6; adjusted for gene positivity pattern in Fig.S3). Above Ct>27.5 (reflecting lower viral loads), all

symptoms declined in prevalence with a trajectory that tracked Ct; between 20-27.5, most symptoms

showed little variation. Interestingly, prevalence of reported loss of taste/smell increased
substantially from ~30% to ~45% between Ct 15-27.5, with smaller increases for shortness of breath.

238 Symptom combinations predicting symptomatic PCR-positive episodes

239 Over the whole study, PPV of any evidence of symptoms for identifying PCR-positive episodes was 240 9%. Including any of the 12 elicited symptoms by definition maximised sensitivity (90% of 241 symptomatic positive episodes reported at least one specific symptom; remainder reported any 242 other symptom considered COVID-19 related only), but substantially increased TPC (8.7) and number 243 of tests (2.3-fold) compared with using the four classic (cough, fever, loss of taste/smell) symptoms 244 (74%, 4.6, 1-fold). For a fixed number of 1-8 symptoms, the choice of whether to maximise sensitivity 245 or area under the receiver operating characteristic (AUROC) curve, or to minimise TPC or the inflation 246 factor, led to different optimal combinations (Table S4). However, these frequently included one or 247 more of the classic four symptoms. Sensitivity was generally higher for combinations including fatigue/weakness and/or headache, but at a cost of higher TPC, particularly for headache. Including 248 249 gastrointestinal symptoms had the lowest TPC and numbers to be tested, but lowest sensitivity. In 250 those \geq 14 days post second dose, sore throat had similar effects on sensitivity and TPC as headache, 251 and in children diarrhoea had a greater benefit for sensitivity (Table S4).

252

Balancing different performance metrics, adding fatigue/weakness to the classic four symptoms
improved sensitivity from 74% to 81%, while dropping the AUROC by <0.01 (0.734 to 0.727) (Fig.7).
However, TPC increased from 4.6 to 5.3, and 1.3 times more people would need testing. This
combination generally performed well across subgroups (Table S5). Adding other symptoms to the
classic four symptoms generally led to lower AUROCs, and at best similar sensitivity (Table S5, Fig.7),
excepting children/adolescents in whom adding headache achieved highest sensitivities when
considering adding only one extra symptom, and also highest AUROC for those aged under 10y

260 (Fig.S4-S8).

261

262 Symptomatology at different stages of SARS-CoV-2 infection

263 Considering symptoms over time in positive episodes with ≥ 2 visits within 35 days (**Table S6**), the most common symptoms presenting after the index positive were fatigue/weakness (8%), headache 264 265 (7%), cough (6%), loss of taste (6%), loss of smell (5%) or muscle ache/myalgia (5%) (Table S7). For 266 most symptoms, Ct values were highest in those never reporting the symptom, lowest in those 267 reporting it initially and subsequently, and intermediate where symptoms were reported at either 268 the initial or subsequent visits only (Fig.S9). The main contrast was loss of taste and loss of smell, 269 where Ct values were lowest in those reporting loss of taste or smell at subsequent visits only 270 (p<0.0001).

271

272 DISCUSSION

273 In a large, randomly selected community-based survey, we demonstrate that overall reporting of any 274 symptoms in new SARS-CoV-2 positives varied substantially over calendar time (40-70%), reflecting changing dominance of specific variants (Alpha, Delta) and positivity rates (higher viral burden (low 275 276 Ct)/symptomatic infections being identified more frequently at (mostly) monthly visits when rates 277 are increasing[5]), but also background incidental changes (e.g. public awareness of SARS-CoV-2-278 associated symptoms, seasonal pathogens, schools re-opening). Additional important differences in the relative frequency of symptom reporting in positive episodes vs negative visits were also 279 280 observed by age, sex, ethnicity and vaccination status. Broadly however, of the 12 symptoms evaluated, the four classic symptoms (fever, cough, loss/change of smell/taste) gave close to optimal 281 282 symptom-based screening, for testing given limited capacity; where additional testing capacity is available adding fatigue/weakness had the greatest improvement in sensitivity (7%) whilst inflating 283

284 TPC by only 15%.

285

286	Whilst the CDC approach of using a broad range of symptoms to prompt testing maximises
287	sensitivity, this approach is associated with substantially higher TPC (8.7 vs 4.6 for classic symptoms)
288	and total tests needed (2.3-fold) with associated costs and capacity requirements. The UK approach
289	of focussing on four classic symptoms has lower sensitivity (74% vs 90%), but higher accuracy to
290	detect SARS-CoV-2 symptomatic infection overall (AUROC 0.734 vs 0.593). Increases in sensitivity
291	from adding symptoms to the four classic symptoms typically either reduced overall accuracy and/or
292	increased TPC and tests needed, highlighting the importance of evaluating several test metrics.
293	Although advantages from including any additional symptoms were limited, those that best
294	improved sensitivity across multiple subgroups included either fatigue/weakness or muscle
295	ache/myalgia, or, in children/adolescents, headache. The REACT study[7] evaluating symptom
296	constellations during the Alpha wave (December-2020/January-2021) suggested adding headache,
297	muscle aches, chills and appetite loss to the classic symptoms. Our survey did not specifically elicit
298	chills or appetite loss, which may partially overlap with fever and nausea/vomiting/abdominal pain;
299	however, we found headache to have poorer specificity (i.e. to be commonly reported in test-
300	negatives), particularly in adults, leading to substantially increased TPC despite improving sensitivity.
301	REACT also suggested having different symptom sets for adults and children in order to optimise
302	sensitivity, which would require careful public health messaging. ZOE[8] suggested an algorithm also
303	including working in healthcare; whilst this could theoretically be programmed into an online test
304	system, such complexity risks gaming the system if individuals cannot otherwise get a test.

305

The main limitation is that the survey collected information on only 12 specific COVID-19 symptoms, plus one generic question, to minimise participant burden. We therefore could not evaluate some symptoms more recently proposed for inclusion in expanded case definitions, such as coryza[13,14].

309 Parents/carers reported symptoms for children; symptom reporting may be affected by other 310 cultural differences we could not adjust for as well as public awareness (e.g. increased reporting of loss of taste/smell once this became a "recognised" symptom). Power was limited within some 311 312 subgroups, e.g. children and specific non-white ethnic groups. Our survey does not include those in 313 care homes and with severe disease admitted to hospital who may have different symptom profiles. 314 Testing was predominantly monthly; although individuals were followed longitudinally, we had 315 limited resolution to assess the short-term evolution of symptoms during an infection. 316 317 The main study strengths are its size and population representativeness, particularly capturing

episodes of mild infection in the community. We took a stringent approach to defining our 'test-

negative' comparator to limit possible contamination from undetected positives/ongoing COVID-19.

320 We report over periods that include different dominant viral variants. We took a pragmatic approach

321 to comparing test performance, taking into account trade-offs between overall accuracy, sensitivity

322 and TPC over different background prevalences, reflecting practical concerns regarding testing

323 capacity, rather than optimising individual criteria.

324

325 Overall, we did not find any major shift away from the importance of the classic four symptoms in 326 positive episodes with the emergence of the Delta variant and vaccine roll-out in the UK. Given their 327 concurrent changes in test-negatives, recent reports of associations with sore throat may reflect 328 background increases in other respiratory infections/hayfever, potentially even with SARS-CoV-2 329 isolated incidentally given that one-third of cases are estimated to be asymptomatic[2]. Currently, we 330 therefore have limited evidence for expanding the case definition beyond the classic four symptoms 331 where universal testing is not practical/affordable, with fatigue/weakness the most promising 332 candidate. However, this requires ongoing monitoring as other respiratory viruses increasingly 333 circulate following lifting of restrictions with vaccine roll-out[15–18], potentially altering the

334 specificity of symptoms in determining SARS-CoV-2 vs other community-acquired infections.

335 **REFERENCES**

- Syangtan G, Bista S, Dawadi P, et al. Asymptomatic SARS-CoV-2 Carriers: A Systematic Review
 and Meta-Analysis. Front Public Heal **2021**; 8:1–10.
- 338 2. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-kelly L. Asymptomatic SARS-CoV-2
- infection : A systematic review and meta-analysis. PNAS **2021**; 118:1–12.
- 340 3. Walker AS, Pritchard E, House T, et al. Ct threshold values, a proxy for viral load in community
- 341 SARS-CoV-2 cases, demonstrate wide variation across populations and over time. Elife **2021**;
- 342 10.
- 4. Lee LYW, Rozmanowski S, Pang M, et al. Severe Acute Respiratory Syndrome Coronavirus 2
- 344 (SARS-CoV-2) Infectivity by Viral Load, S Gene Variants and Demographic Factors, and the
- 345 Utility of Lateral Flow Devices to Prevent Transmission. Clin Infect Dis **2021**; :1–9.
- 346 5. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2

347 infections in the United Kingdom. Nat Med **2021**; Available at:

- 348 http://dx.doi.org/10.1038/s41591-021-01410-w.
- Chan AT, Brownstein JS. Putting the Public Back in Public Health Surveying Symptoms of
 Covid-19. N Engl J Med **2020**; 383:e45. Available at: nejm.org.
- 351 7. Elliott J, Whitaker M, Bodinier B, et al. Symptom reporting in over 1 million people:
- 352 community detection of COVID-19. medRxiv **2021**;
- 8. Canas LS, Sudre CH, Capdevila Pujol J, et al. Early detection of COVID-19 in the UK using self-
- 354 reported symptoms: a large-scale, prospective, epidemiological surveillance study. Lancet
- 355 Digit Heal **2021**; 7500:1–12. Available at: http://dx.doi.org/10.1016/S2589-7500(21)00131-X.
- 356 9. Fragaszy E, Shrotri M, Geismar C, et al. Symptom profiles and accuracy of clinical definitions
- for COVID-19 in the community. Results of the Virus Watch community cohort. medRxiv **2021**;
- 358 :2021.05.14.21257229. Available at:

- 360 10. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and
- 361 transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet
- 362 Public Heal **2021**; 6:e335–e345.
- 363 11. What are the new top 5 COVID symptoms? 2021. Available at:
- 364 https://covid.joinzoe.com/post/new-top-5-covid-symptoms. Accessed 9 August 2021.
- 12. Pouwels KB, House T, Pritchard E, et al. Community prevalence of SARS-CoV-2 in England from
- 366 April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public
- 367 Heal **2021**; 6:e30–e38.
- Crozier A, Dunning J, Rajan S, Semple MG, Buchan IE. Could expanding the covid-19 case
 definition improve the UK's pandemic response? BMJ **2021**; 374:17–20.
- 370 14. Sohal A. Open letter to Chris Whitty and Susan Hopkins: Change covid-19 case definition in
 371 line with WHO to save lives. BMJ **2021**; 372:2021.
- 15. Huang QS, Wood T, Jelley L, et al. Impact of the COVID-19 nonpharmaceutical interventions
- on influenza and other respiratory viral infections in New Zealand. Nat Commun **2021**; 12:1–7.
- 374 Available at: http://dx.doi.org/10.1038/s41467-021-21157-9.
- Britton PN, Hu N, Saravanos G, et al. COVID-19 public health measures and respiratory
 syncytial virus. Lancet Child Adolesc Heal **2020**; 4:e42–e43.
- 17. Sherman AC, Babiker A, Sieben AJ, et al. The Effect of Severe Acute Respiratory Syndrome
- 378 Coronavirus 2 (SARS-CoV-2) Mitigation Strategies on Seasonal Respiratory Viruses: A Tale of 2
- 379 Large Metropolitan Centers in the United States. Clin Infect Dis **2021**; 72:E154–E157.
- 18. Park S, Michelow IC, Choe YJ. Shifting Patterns of Respiratory Virus Activity Following Social
- 381 Distancing Measures for Coronavirus Disease 2019 in South Korea. J Infect Dis 2021; :1–7.

Contributors: This specific analysis was designed by ASW, KBP, PCM, NS, DWE, TH, DC, TEAP, K-DV. KDV conducted the statistical analysis of the survey data. K-DV, NS, PCM, ASW drafted the manuscript.
All authors contributed to interpretation of the study results, and revised and approved the
manuscript for intellectual content. K-DV is the guarantor and accepts full responsibility for the work
and conduct of the study, had access to the data, and controlled the decision to publish. The
corresponding author (K-DV) attests that all listed authors meet authorship criteria and that no
others meeting the criteria have been omitted.

389

Funding: This study is funded by the Department of Health and Social Care with in-kind support from 390 391 the Welsh Government, the Department of Health on behalf of the Northern Ireland Government 392 and the Scottish Government. K-DV, KBP, ASW, TEAP, NS, DE are supported by the National Institute 393 for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated 394 Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health 395 England (PHE) (NIHR200915). ASW and TEAP are also supported by the NIHR Oxford Biomedical 396 Research Centre. KBP is also supported by the Huo Family Foundation. ASW is also supported by core 397 support from the Medical Research Council UK to the MRC Clinical Trials Unit [MC UU 12023/22] 398 and is an NIHR Senior Investigator. PCM is funded by Wellcome (intermediate fellowship, grant ref 399 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship award. DWE is supported by a 400 Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. NS is an Oxford Martin Fellow and 401 an NIHR Oxford BRC Senior Fellow. The views expressed are those of the authors and not necessarily 402 those of the National Health Service, NIHR, Department of Health, or PHE. The funder/sponsor did 403 not have any role in the design and conduct of the study; collection, management, analysis, and 404 interpretation of the data; preparation, review, or approval of the manuscript; and decision to 405 submit the manuscript for publication. All authors had full access to all data analysis outputs (reports 406 and tables) and take responsibility for their integrity and accuracy.

407

408	PCM received funding from the Wellcome Trust [110110/Z/15/Z]. For the purpose of Open Access,
409	the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version
410	arising from this submission.
411	
412	Competing interests: All authors have completed the ICMJE uniform disclosure from at
413	www.icmje.org/coi_disclore.pdf. DWE declares lecture fees from Gilead outside the submitted work.
414	No other author has a conflict of interest to declare.
415	
416	Ethical approval: The study received ethical approval from the South Central Berkshire B Research
417	Ethics Committee (20/SC/0195).
418	
419	Data sharing: Data are still being collected for the COVID-19 Infection Survey. De-identified study
420	data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for
421	accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. For further
422	information about accreditation, contact Research.Support@ons.gov.uk or visit the SRS website.
423	
424	Transparency: The lead authors affirm that the manuscript is an honest, accurate, and transparent
425	account of the study design being reported, no important aspects of the study have been omitted,
426	and any discrepancies from the study as originally planned (and, if relevant, registered) have been
427	explained. Dissemination to participants and related patient and public communities: Results of
428	individual tests were communicated to the participants. Overall study results were disseminated
429	through the preprint of the study. Findings were disseminated in lay language in the national and
430	local press.
431	
432	Acknowledgements: We are grateful for the support of all COVID-19 Infection Survey participants.
433	Office for National Statistics: Sir Ian Diamond, Emma Rourke, Ruth Studley, Tina Thomas. Office for

434 National Statistics COVID-19 Infection Survey Analysis and Operations teams, in particular: Daniel 435 Ayoubkhani, Russell Black, Antonio Felton, Megan Crees, Joel Jones, Lina Lloyd, Esther Sunderland. 436 University of Oxford, Nuffield Department of Medicine: Ann Sarah Walker, Derrick Crook, Philippa C 437 Matthews, Tim Peto, Emma Pritchard, Nicole Stoesser, Karina-Doris Vihta, Jia Wei, Alison Howarth, 438 George Doherty, James Kavanagh, Kevin K Chau, Sarah Cameron, Phoebe Tamblin-Hopper, Magda 439 Wolna, Rachael Brown, Stephanie B Hatch, Daniel Ebner, Lucas Martins Ferreira, Thomas Christott, 440 Brian D Marsden, Wanwisa Dejnirattisai, Juthathip Mongkolsapaya, Sarah Hoosdally, Richard Cornall, David I Stuart, E Yvonne Jones, Gavin Screaton. University of Oxford, Nuffield Department of 441 442 Population Health: Koen Pouwels. University of Oxford, Big Data Institute: David W Eyre, Katrina 443 Lythgoe, David Bonsall, Tanya Golubchik, Helen Fryer. University of Oxford, Radcliffe Department of 444 Medicine: John Bell. University of Manchester: Thomas House. Public Health England: John Newton, 445 Julie Robotham, Paul Birrell. IQVIA: Helena Jordan, Tim Sheppard, Graham Athey, Dan Moody, Leigh 446 Curry, Pamela Brereton. Glasgow Lighthouse Laboratory: Jodie Hay, Harper VanSteenhouse. National 447 Biocentre: Anna Godsmark, George Morris, Bobby Mallick, Phil Eeles. Oxford University Hospitals NHS Foundation Trust: Stuart Cox, Kevin Paddon, Tim James, Sarah Cameron, Phoebe Tamblin-448 449 Hopper, Magda Wolna, Rachael Brown. Department of Health: Jessica Lee.

451 **FIGURE LEGENDS**

- 452 *Figure 1* Percentage self-reporting any evidence of symptoms out of all positive episodes and
- 453 *negative visits, and percentage reporting each specific symptom of those reporting any*
- 454 symptoms
- 455 *Figure 2* Probability of reporting any evidence of symptoms (first column), and specific classic
- 456 symptoms (second column), gastrointestinal symptoms (fourth column) and other symptoms
- 457 (third column) in those with evidence of symptoms, by calendar time in positive episodes (top
- 458 *row*) and negative visits (*bottom row*).
- 459 *Figure 3* Probability of reporting any evidence of symptoms (first column), and specific classic
- 460 symptoms (second column), gastrointestinal symptoms (fourth column) and other symptoms
- 461 (third column) in those with evidence of symptoms, by age in positive episodes (**top row**) and
- 462 *negative visits* (*bottom row*).
- 463 *Figure 4* Odds ratios (95% CI) of reporting any evidence of symptoms, as well as each of the
- 464 12 symptoms in those with evidence of symptoms, in positive episodes (red) and negative
- 465 visits (turquoise) by sex (female vs male, *left*), and ethnicity (non-white vs white, *right*). p-
- 466 values are heterogeneity tests between the effects of sex and ethnicity on reporting
- 467 symptoms in positive episodes vs negative visits.
- 468 *Figure 5* Odds ratios (95% CI) of reporting any evidence of symptoms, as well as each of the
- 469 *12 symptoms in those with evidence of symptoms, in positive episodes (red) and negative*
- 470 visits (turquoise) by vaccination status (episodes/visits ≥ 21 days from 1st vaccine and before
- 471 2^{nd} vaccine vs pre-vaccination, *left*, and \geq 14 days from 2^{nd} vs pre-vaccination, *right*). p-values
- 472 are heterogeneity tests between the effects of vaccination on reporting symptoms in positive

- 473 episodes vs negative visits.
- 474 *Figure 6* Probability of reporting any evidence of symptoms (first column), and the probability
- 475 of reporting each of the 12 symptoms in those with evidence of symptoms, by Ct value
- 476 *Figure 7* Performance of individual symptoms, as well as the classic four symptoms (cough,
- 477 *fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and*
- 478 any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of
- 479 symptoms in terms of sensitivity and overall accuracy (AUROC).



Figure 1 Percentage self-reporting any evidence of symptoms out of all positive episodes and negative visits, and percentage reporting each specific symptom of those reporting any symptoms

Note: wild-type defined as S-gene positive before 17 November 2020; Alpha-compatible defined as S-gene negative from 17 November 2020 through 17 May 2021, Delta-compatible defined as S-gene positive from 17 May 2021. Post-vaccination positives split into not yet vaccinated, those 21 days after first vaccination and before second vaccination, and 14 days or more after second vaccination. The two median values are median Ct in all and symptomatic positive episodes in each group. See **Fig.6** for associations between Ct and symptoms. Red dashed lines indicate symptom clusters based on hierarchical clustering (**Fig.S2**).



Figure 2 Probability of reporting any evidence of symptoms (first column), and specific classic symptoms (second column), gastrointestinal symptoms (fourth column) and other symptoms (third column) in those with evidence of symptoms, by calendar time in positive episodes (**top row**) and negative visits (**bottom row**).

Note: models adjusted for age, sex, ethnicity (presented at the reference category age 45, male, white). The top and bottom rows have different scales for the y-axis. Dashed lines at 17 November 2020 and 17 May 2021 indicate the emergence of Alpha and Delta respectively, see **Fig.S1**.



Figure 3 Probability of reporting any evidence of symptoms (first column), and specific classic symptoms (second column), gastrointestinal symptoms (fourth column) and other symptoms (third column) in those with evidence of symptoms, by age in positive episodes (top row) and negative visits (bottom row).

Note: models adjusted for calendar date, sex, ethnicity (reference category 1 January 2021, male, white). The top and bottom row have different scales for the y-axis.



Figure 4 Odds ratios (95% CI) of reporting any evidence of symptoms, as well as each of the 12 symptoms in those with evidence of symptoms, in positive episodes (red) and negative visits (turquoise) by sex (female vs male, **left**), and ethnicity (non-white vs white, **right**). p-values are heterogeneity tests between the effects of sex and ethnicity on reporting symptoms in positive episodes vs negative visits.

Note: models adjusted for calendar date (**Fig.2**), age (**Fig.3**), sex and ethnicity. Where 95% CI cross 1, there is no evidence that sex/ethnicity affects the odds of reporting that symptom **given evidence of symptoms** in positive episodes/negative visits. Where there is evidence of heterogeneity, there is a different effect of sex/ethnicity on reporting the symptom in positive episodes vs negative visits.



Figure 5 Odds ratios (95% CI) of reporting any evidence of symptoms, as well as each of the 12 symptoms in those with evidence of symptoms, in positive episodes (red) and negative visits (turquoise) by vaccination status (episodes/visits \geq 21 days from 1st vaccine and before 2nd vaccine vs pre-vaccination, **left**, and \geq 14 days from 2nd vs pre-vaccination, **right**). p-values are heterogeneity tests between the effects of vaccination on reporting symptoms in positive episodes vs negative visits.

Note: models adjusted for calendar date (**Fig.2**), age (**Fig.3**), sex (**Fig.4**) and ethnicity (**Fig.5**). Where 95% CI cross 1, there is no evidence that sex/ethnicity affects the odds of reporting that symptom **given evidence of symptoms** in positive episodes/negative visits. Where there is evidence of heterogeneity, there is a different effect of sex/ethnicity on reporting the symptom in positive episodes vs negative visits.



Figure 6 Probability of reporting any evidence of symptoms (first column), and the probability of reporting each of the 12 symptoms in those with evidence of symptoms, by Ct value

Note: models adjusted for calendar date (Fig.2), age (Fig.3), sex and ethnicity (Fig.4) (reference category 1 January 2021, 45, male, white). See Fig.S3 for models also adjusting for S-gene positivity pattern with similar results



Figure 7 Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC).

Note: Right hand panel is an expanded version of the top right corner of the left panel (red box, AUROC >90th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation. TPC=1/positive predictive value. By definition, as the number of symptoms increases, sensitivity also increases.

Note: abbreviations: c – classic, Fever - F, Headache - H, Muscle ache/myalgia - MAM, Weakness/tiredness - FW, Nausea/vomiting - NV, Abdominal pain - AP, Diarrhoea - D, Sore throat - ST, Cough - C, Shortness of breath - SOB, Loss of taste - LT, Loss of smell – LS, Loss of taste or smell – LTS

Supplementary Material

Supplementary Methods

The presence of three SARS-CoV-2 genes (ORF1ab, N, S) was identified using real-time polymerase chain reaction (RT-PCR) with the TaqPath RT-PCR COVID-19 kit (Thermo Fisher Scientific, Waltham, MA, USA), analysed using UgenTec Fast Finder 3.300.5 (TaqMan 2019-nCoV assay kit V2 UK NHS ABI 7500 v2.1; UgenTec, Hasselt, Belgium).

Choice of negative visits in the comparator group

As a comparator group, we initially included all visits where PCR tests were negative, and then excluded visits where symptoms could plausibly be related to ongoing effects of COVID-19 or long COVID, where there was a high pre-test probability that the participant actually had a new COVID-19 infection that had not been detected in the survey, or where symptoms were likely driven by recent vaccination. Specifically, we excluded all negative visits (numbers in Table S1):

- 1. From -90 days before the first S-antibody positive blood test in the study prior to vaccination, where such antibody results are likely to represent previous undetected infection (these results were available only in a random subset of the population);
- From -35 days before the first swab positive onwards from individuals who ever 2. tested PCR positive in the study or positive on either PCR or LFD in the linked English testing programme (to avoid ongoing long COVID symptoms,² and COVIDrelated symptoms occurring shortly before the positive test):
- 3. From -35 days before any self-reported positive swab test result onwards (for the same reason; reflecting the fact that individuals may have obtained tests elsewhere)
- 4. From a small number of individuals who reported either loss of taste or loss of smell at their first study visit and had no national testing programme result within [-21,+21]days (all before 1 July 2020), given the high specificity of this symptom for COVID-19 infection, the fact that it would have been impossible for these individuals to get an external test at the time and the potential for subsequent symptoms to represent long COVID:
- 5. Where participants reported self-isolating OR contact with **definite** positives in the preceding 28 days (since these individuals have much higher risk of SARS-CoV-2 infection which may not have been detected) and the previous and the next visit (because of higher risk of unidentified positivity, and because they may have been contact traced through the national training programme they may be more likely to report symptoms through recall bias, regardless of status);
- Occurring within [-7,+14 days] of either first or second vaccination date³, to avoid the 6. inclusion of common symptoms caused by vaccination in the test-negative comparator group and to reflect the possibility of small inaccuracies in reported date of vaccination for some participants.

Time windows were arbitrary but aligned with other analyses or windows for considering symptoms associated with positive episodes.

Subgroups

In order to assess the impact of various changes over the course of the epidemic, we considered symptoms overall in all positive episodes, and in specific subgroups, as follows:

> a. S-gene present before 17/Nov/2020 (wild-type) vs S-gene absent from 17/Nov/2020 to 17/May/2020 (Alpha-compatible) vs S-gene present from

17/May/2020 onwards (Delta-compatible) (Fig.S1); all restricted to Ct<30 to increase the chance that the survey positive test was closer to the start of the infection

- b. Ct<30 or \geq 30 as a proxy for higher viral load (where symptoms may be more completely ascertained if the infection is identified close to onset) vs lower viral load
- c. Up to 0 days before 1st vaccination date or unvaccinated, from 21 days post 1st vaccination date to 13 days post 2nd vaccination date inclusive, from 14 days post 2nd vaccination date onwards. Episodes/tests 0-20 days after first vaccination were excluded as symptoms may be due to side-effects.
- d. Age groups 2-5, 6-10, 11-15, 16-44, 45-64, 65+ years
- e. All positive episodes split between before 1/Sep/2020, 1/Sep/2020-17/Nov/2020, 17/Nov/2020-1/Mar/2021, 1/Mar/2021-17/May/2021, 17/May/2021-17/Jul/2021 on the basis of background incidental symptoms in negative visits (different background rates could be driven either by epidemic dynamics and/or other infections being more prevalent during certain periods)

Cycle threshold (Ct) values

Each positive test has a Ct value for each positive gene, leading to 1-3 individual Ct values per positive result. As the Spearman correlation between Ct values for each pair of genes (when present together) was very high (>0.98), we first took the arithmetic mean of all Ct values for detected genes for each positive as the single Ct value per positive test. We then took the minimum of these Ct values across all positive tests in an episode as the Ct value for each positive episode.

Generalised additive models

In regression models for reporting any evidence of symptoms and specific symptoms in those with evidence of symptoms in positive episodes and negative visits, we truncated age at 85v and Ct at the 5th and 95th percentiles in order to avoid undue influence of outliers. Age was modelled as smoothing spline. Due to small numbers (**Table S3**) we were only able to investigate differences by self-reported ethnicity as white vs non-white.

bam(cbind(n_withsymptom, n_withoutsymptom) ~ s(study_day, bs="bs", k=15, by=Sars_COV_2_positivity) + s(age_at_visit, bs="bs", k=15, by=Sars_COV_2_positivity) + sex:Sars_COV_2_positivity + ethnicity_wo:Sars_COV_2_positivity + sex + ethnicity_wo + Sars_COV_2_positivity, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12)

bam(cbind(n withsymptom, n withoutsymptom) ~ vaccinated:Sars_COV_2_positivity + vaccinated + s(study_day, bs="bs", k=15, by=Sars_COV_2_positivity) + s(age_at_visit, bs="bs", k=15, by=Sars_COV_2_positivity) + sex:Sars COV 2 positivity + ethnicity wo:Sars COV 2 positivity + sex + ethnicity_wo + Sars_COV_2_positivity, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12)

In positive episodes only:

bam(cbind(n_withsymptom, n_withoutsymptom) ~ s(ct mean, bs="bs", k=5) +

 $s(study_day, bs="bs", k=15) +$ s(age_at_visit, bs="bs", k=15) + sex + ethnicity wo, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12)

Also adjusting for S-gene positivity (present/absent/unknown):

bam(cbind(n withsymptom, n withoutsymptom) ~ $s(ct _mean, bs="bs", k=5) +$ S gene positivity pattern + $s(study_day, bs="bs", k=15) +$ s(age_at_visit, bs="bs", k=15) + sex + ethnicity_wo, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12)

Performance metrics

For each combination of symptoms considered, we calculated the number of true positives $(\geq 1$ symptom from the combination being considered reported for a positive episode; TP), false positives (≥1 symptom reported for a negative visit; FP), true negatives (symptoms in the combination not reported for a negative visit; TN), false negatives (symptoms in the combination not reported in a positive episode; FN). We compared sensitivity=TP/(TP+FN); specificity=TN/(TN+FP); positive predictive value=TP/(TP+FP) (PPV); negative predictive value=TN/(TN+FN) (NPV); area under the receiver operating characteristic curve (AUROC), the area under the curve of specificity and 1-sensitivity, which, in this case where we have a binary outcome and a binary exposure, is 0.5*(sensitivity+specificity); tests per case identified=1/PPV (TPC); and the inflation factor=episodes/visits with ≥ 1 symptom/episodes/visits with classic symptoms.

Results

Defining the negative visit comparator group

Table S1 shows the total number of test-negative visits and the number of participants in which they occur, in all PCR negative visits and restricting to those visits with evidence of symptoms only, for each step of the hierarchical restriction of test-negative visits to form the comparator. This was done in order to exclude potential contamination from undetected positives, ongoing symptoms after detected positives, and symptoms due to vaccination. Overall, 75% of test-negative visits in 93% participants with any test-negative visit were retained in analyses, and 62% of test-negative visits where any symptoms were reported in 68% of participants with any test-negative visit where any symptoms were reported. Most test-negative visits were excluded because of self-isolation or contact with definite positives. The larger exclusion of test-negative visits where any symptoms were reported, despite the fact that symptoms were not a reason for exclusion (with the exception of visits from a small number of individuals reporting loss of taste/smell in 2020 before tests were available) illustrate the likely contamination of all test-negative visits with both undetected positives and ongoing symptoms post COVID-19 infection (Table S2).

Comparing the probability of reporting specific symptoms in negative visits with evidence of symptoms over time before (Fig.S10) and after (Fig.2) the final exclusion of negative visits that occurred within [-7,+14 days] of either first or second vaccination date, the substantially higher probabilities of reporting fever, headache, fatigue weakness, muscle ache myalgia and nausea-vomiting in the first quarter of 2021 are plausibly driven by side effects of vaccination, as these probabilities markedly reduce after the exclusion.



Figure S1. Percentage of positive episodes with each S-gene positivity pattern over time

Apr-20 May-20 Jun-20 Jun-20 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 May-21 Apr-21 May-21 Jun-21 Jun-21 Jun-21 Aug-21 Week

Note: vertical lines at 17 November 2020 and 17 May 2021. S-gene positive if the S-gene was ever detected within any positive test in the episode (by definition, with N/ORF1ab/both) (wild-type/Delta-compatible), otherwise S-gene negative if positive at least once for ORF1ab+N (Alpha-compatible), otherwise S-gene unknown (N-only/ORF1ab-only).





Variant: wild-type compatible, Ct<30 (left), Alpha-compatible, Ct<30 (middle) c. and Delta-compatible, Ct<30 (right)



d. Not yet vaccinated (left), 21 days after first vaccination and before second vaccin ation (middle) and 14 days or more after second vaccination (right)



Note: different scales.
Figure S3. Probability of reporting any evidence of symptoms, as well as the probability of reporting each of the 12 symptoms in those with evidence of symptoms by mean Ct (model adjusted for age, sex and ethnicity and S-gene positivity pattern).



Figure S4. Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC).



Note: Bottom row is an expanded version of the top right corner of the top row panels (red box, AUROC >90th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation. TPC=1/positive predictive value. By definition, as the number of symptoms increases, sensitivity also increases.

Note: abbreviations: c – classic, Fever - F, Headache - H, Muscle ache/myalgia - MAM, Weakness/tiredness - FW, Nausea/vomiting - NV, Abdominal pain - AP, Diarrhoea - D, Sore throat - ST, Cough - C, Shortness of breath - SOB, Loss of taste - LT, Loss of smell – LS, Loss of taste or smell – LTS

Figure S5. Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC).



Note: Bottom row is an expanded version of the top right corner of the top row panels (red box, AUROC >90th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation. TPC=1/positive predictive value. By definition, as the number of symptoms increases, sensitivity also increases.

Note: abbreviations: c – classic, Fever - F, Headache - H, Muscle ache/myalgia - MAM, Weakness/tiredness - FW, Nausea/vomiting - NV, Abdominal pain - AP, Diarrhoea - D, Sore throat - ST, Cough - C, Shortness of breath - SOB, Loss of taste - LT, Loss of smell – LS, Loss of taste or smell – LTS

Figure S6. Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC).



Note: Bottom row is an expanded version of the top right corner of the top row panels (red box, AUROC >90th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation. TPC=1/positive predictive value. By definition, as the number of symptoms increases, sensitivity also increases.

Note: abbreviations: c – classic, Fever - F, Headache - H, Muscle ache/myalgia - MAM, Weakness/tiredness - FW, Nausea/vomiting - NV, Abdominal pain - AP, Diarrhoea - D, Sore throat - ST, Cough - C, Shortness of breath - SOB, Loss of taste - LT, Loss of smell – LS, Loss of taste or smell – LTS

Figure S7. Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC).





Note: Bottom row is an expanded version of the top right corner of the top row panels (red box, AUROC >90th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation. TPC=1/positive predictive value. By definition, as the number of symptoms increases, sensitivity also increases.

Note: abbreviations: c – classic, Fever - F, Headache - H, Muscle ache/myalgia - MAM, Weakness/tiredness - FW, Nausea/vomiting - NV, Abdominal pain - AP, Diarrhoea - D, Sore throat - ST, Cough - C, Shortness of breath - SOB, Loss of taste - LT, Loss of smell – LS, Loss of taste or smell – LTS

Figure S8. Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC).





Note: Bottom row is an expanded version of the top right corner of the top row panels (red box, AUROC >90th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation. TPC=1/positive predictive value. By definition, as the number of symptoms increases, sensitivity also increases.

Note: abbreviations: c – classic, Fever - F, Headache - H, Muscle ache/myalgia - MAM, Weakness/tiredness - FW, Nausea/vomiting - NV, Abdominal pain - AP, Diarrhoea - D, Sore throat - ST, Cough - C, Shortness of breath - SOB, Loss of taste - LT, Loss of smell – LS, Loss of taste or smell – LTS

Figure S9. Distribution of Ct for each of the 12 symptoms in positive episodes with symptoms absent at all visits within 35 days of the index positive (00), absent at the index positive, but present at least one subsequent visit (01), present at the index positive, but absent at subsequent visits (10), present initially and at least one subsequent visit (11)



Figure S10. Probability of reporting specific symptoms at negative-visits with any evidence of symptoms before the final exclusion of negative visits where visit date is within [-7,+14] days of date of either first or second vaccination



Note: adjusted for sex, age and ethnicity (reference category age 45, male, white ethnicity). Vaccination programme started 8 December 2020, but increased in magnitude in January 2021.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.19.21262231; this version posted August 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

Table S1 Negative visits; summary of exclusions

Negative visits	With and without results symptoms	eported	With reported symptoms			
excluding	Visits (% from first row)	Participants (% from first row)	Visits (% from first row)	Participants (% from first row)		
0	5,095,824	489,804	209,281	142,513		
1	4,981,365 (98%)	482,963 (99%)	202,429 (97%)	138,393 (97%)		
1+2	4,795,502 (94%)	471,641 (96%)	189,041 (90%)	130,242 (91%)		
1+2+3	4,708,088 (92%)	464,232 (95%)	183,380 (88%)	126,777 (89%)		
1+2+3+4	4,702,276 (92%)	463,638 (95%)	182,128 (87%)	126,183 (89%)		
1+2+3+4+5	4,172,632 (82%)	458,510 (94%)	149,822 (72%)	108,773 (76%)		
1+2+3+4+5+6	3,806,692 (75%)	457,215 (93%)	130,612 (62%)	97,186 (68%)		
Summary	130,612/3,806,692 (3	3.4%) of negative v	isits reported sym	ptoms		

130,612/3,806,692 (3.4%) of negative visits reported symptoms 97,816/457,215 (21%) of participants in the negative cohort reported symptoms

0. Visits where PCR test negative

1. <u>From -90 days before</u> the first antibody positive test in the study prior to **vaccination**, where antibody results are likely to represent previous undetected infection;

 <u>From -35 days before</u> the first positive onwards from individuals who ever tested PCR positive in the study or in the linked English testing programme (to avoid ongoing long COVID symptoms,² and COVID-19-related symptoms shortly before the positive test);

3. **From -35 days before** any self-reported positive swab test result onwards (for the same reason; reflecting the fact that individuals may have obtained tests elsewhere)

4. From a small number of individuals who reported either loss of taste or loss of smell at their first study visit and had no national testing programme result within [-21,+21] days (all before 1 July 2020), given the high specificity of this symptom for COVID-19 infection, the fact that it would have been impossible for these individuals to get an external test and the potential for subsequent symptoms to represent long COVID

- 5. Where participants reported self-isolating OR contact with <u>definite</u> positives in the preceding 28 days (since these individuals have much higher risk of SARS-CoV-2 infection which may not have been detected) and the <u>previous</u> <u>and the next visit</u> (because of higher risk of unidentified positivity, and because they may have been contact traced through the national training programme they may be more likely to report symptoms through recall bias, regardless of status)
- 6. Occurring within [-7,+14 days] of either first or second vaccination date³, to avoid the inclusion of common symptoms caused by vaccination in the test-negative comparator group and to reflect the possibility of small inaccuracies in reported date of vaccination for some participants

Table S2 Numbers with each symptom in test-negative visits and percentage remaining from each as exclusion becomes stricter

	Visits where PCR test negative	Additionally, exclude <u>all</u> <u>visits from -90</u> <u>days before</u> first antibody positive test in CIS before vaccination onwards	Exclude <u>all visits</u> <u>from -35</u> <u>days before</u> the first positive from individuals ever tested PCR positive in the study onwards	Additionally, exclude <u>all visits</u> <u>from -35</u> <u>davs before</u> the first positive from individuals ever tested positive in the linked T&T data onwards	Additionally, exclude <u>all</u> <u>visits from -35</u> <u>days before</u> first self-reporting positive swab and date onwards	Additionally, exclude <u>all</u> <u>visits</u> from individuals who report either loss of taste or loss of smell at their first visit and have no T&T result within [-21,+21] days	Additionally, exclude <u>specific</u> <u>visits</u> where participants report self- isolating and the <u>previous and</u> <u>the next visit</u>	Additionally, exclude <u>specific</u> <u>visits</u> where participants report contact with <u>definite</u> posit ives in last 28 days and the <u>previous and</u> <u>the next visit</u>	Additionally, exclude (negative) visits occurring within [-7,+14 days] of either first or second vaccination date
Symptom		Number report	ing this symptom af	ter exclusions, i.e. r	emaining in analys	is (% of those repor	ting this symptom	in all PCR negative	visits)
loss of smell	7,460	6,748 (90%)	5,804 (78%)	4,986 (67%)	4,542 (61%)	3,899 (52%)	3,066 (41%)	2,750 (37%)	2,418 (32%)
loss of taste	7,572	6,941 (92%)	6,036 (80%)	5,242 (69%)	4,806 (63%)	4,193 (55%)	3,125 (41%)	2,779 (37%)	2,415 (32%)
loss of taste or									
smell	10,655	9,782 (92%)	8,563 (80%)	7,545 (71%)	6,968 (65%)	6,103 (57%)	4,746 (45%)	4,248 (40%)	3,706 (35%)
abdominal pain		12,619 (97%)	12,082 (93%)	11,749 (91%)	11,374 (88%)	11,264 (87%)	9,572 (74%)	8,894 (69%)	7,682 (59%)
diarrhoea	13,335	12,961 (97%)	12,454 (93%)	12,126 (91%)	11,753 (88%)	11,635 (87%)	9,921 (74%)	9,210 (69%)	7,936 (60%)
nausea	14,100	13,671 (97%)	13,074 (93%)	12,631 (90%)	12,250 (87%)	12,127 (86%)	10,228 (73%)	0.420.(670/)	7 279 (570/)
vomiting shortness of	14,100	13,071 (97%)	13,074 (93%)	12,031 (90%)	12,230 (87%)	12,127 (80%)	10,228 (75%)	9,439 (67%)	7,328 (52%)
breath	16,227	15,399 (95%)	14,273 (88%)	13,391 (83%)	12,790 (79%)	12,541 (77%)	9,659 (60%)	8,947 (55%)	7,768 (48%)
fever	16,616	16,147 (97%)	15,486 (93%)	14,975 (90%)	14,427 (87%)	14,296 (86%)	11,363 (68%)	10,480 (63%)	7,034 (42%)
muscle ache		· · · · · ·	· 、 、	, , , , ,	· 、 、 /		· · · · ·	, , , , ,	· 、 ,
myalgia	26,621	25,623 (96%)	24,229 (91%)	23,271 (87%)	22,360 (84%)	22,114 (83%)	18,604 (70%)	17,266 (65%)	11,636 (44%)
fatigue	10.000	20 540 (0 (0))	26.214 (000)		00.075(0000)	22.007 (020)	07 540 (600()		10 204 (420()
weakness	40,220	38,540 (96%)	36,214 (90%)	34,603 (86%)	33,276 (83%)	32,907 (82%)	27,549 (68%)	25,367 (63%)	18,704 (47%)
sore throat	45,159	44,024 (97%)	42,565 (94%)	41,653 (92%)	40,472 (90%)	40,183 (89%)	34,842 (77%)	32,020 (71%)	29,156 (65%)
cough	46,561	45,176 (97%)	43,292 (93%)	41,936 (90%)	40,519 (87%)	40,185 (86%)	33,641 (72%)	30,920 (66%)	28,428 (61%)
headache	55,608	53,896 (97%)	51,696 (93%)	50,191 (90%)	48,720 (88%)	48,384 (87%)	42,559 (77%)	38,950 (70%)	30,558 (55%)
any evidence of symptoms	209,281	202,429 (97%)	194,322 (93%)	189,041 (90%)	183,380 (88%)	182,128 (87%)	161,936 (77%)	149,822 (72%)	130,612 (62%)

Table S3 Characteristics of all and symptomatic positive episodes and all and symptomatic negative visits

	Positive episodes			Negative visits	
	All positive episodes (N=27,869)	Symptomatic positive episodes (N=13,427)	All negative visits (N=3,806,692)		Symptomatic negative visits (N=130,612)
Age (years)	42 (22-58)	42 (25-56)	52 (32-66)		48 (32-63)
2-5	672 (2%)	180 (1%)	84,200 (2%)		3,508 (3%)
6-10	1,542 (6%)	462 (3%)	175,245 (5%)		5,695 (4%)
11-15	2,419 (9%)	1,004 (7%)	204,871 (5%)		6,677 (5%)
16-44	10,379 (37%)	5,520 (41%)	1,055,350 (28%)		42,378 (32%)
45-64	8,486 (30%)	4,588 (34%)	1,218,093 (32%)		43,481 (33%)
65+	4,371 (16%)	1,673 (12%)	1,068,933 (28%)		28,873 (22%)
Male	13,447 (48%)	6,232 (46%)	1,803,043 (47%)		56,289 (43%)
Female	14,422 (52%)	7,195 (54%)	2,003,649 (53%)		74,323 (57%)
White	24,877 (89%)	12,116 (90%)	3,534,865 (93%)		122,251 (94%)
Asian	1,579 (6%)	679 (5%)	143,744 (4%)		3,825 (3%)
Black	406 (1%)	156 (1%)	33,418 (1%)		930 (1%)
Mixed	689 (2%)	312 (2%)	64,276 (2%)		2,544 (2%)
Other	317 (1%)	163 (1%)	29,958 (1%)		1,052 (1%)
Not yet vaccinated	23,308 (84%)	11,192 (83%)	2,769,853 (73%)		98,621 (76%)
\geq 21 days from 1 st vaccine, before 2 nd vaccine	551 (2%)	230 (2%)	291,874 (8%)		8,878 (7%)
\geq 14 days from 2 nd vaccine	1,969 (7%)	1,010 (8%)	557,849 (15%)		16,753 (13%)

Gene positivity pattern	All positive episo	odes	Symptomatic positive episodes			
	Ct<30	Ct ≥30	Ct<30	Ct ≥30		
S-gene present before 17/Nov/2020 (wild-type)	3,995	578	2,412	229		
S-gene absent from 17/Nov/2020 to 17/May/2020	6,324	2,561	3,900	849		
(Alpha-compatible) S-gene present from 17/May/2020 onwards (Delta-compatible)	3,309	724	2,096	293		

Note: showing median (IQR) or n (col %). Overall PPV of any evidence of symptoms predicting PCR positive episodes is 9%.

Table S4 Sensitivity, specificity, test per case (TPC), AUROC and inflation factor for various symptom combinations across the whole study period and split by Ct valuet, variant, vaccination status and age

Criteria	Symptoms	sensitivity	specificity	AUROC	трс	inflation
	All positives					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	90	29	0.593	8.7	2.3
4 classic symptoms	Fever or cough or loss of taste or loss of smell	74	73	0.734	4.6	1
4 classic symptoms + fatigue/weakness** 4 classic symptoms +	Fever or cough or loss of taste or loss of smell or fatigue/weakness	81	64	0.727	5.3	1.3
fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	83	60	0.716	5.7	1.4
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache	83	52	0.675	6.6	1.6
4 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness	71	81	0.759	3.6	0.8
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath	61	87	0.741	3	0.5
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or nausea/vomiting	49	88	0.682	3.5	0.5
1 symptom: highest sensitivity	fatigue/weakness	54	86	0.7	3.6	0.6
1 symptom: highest AUROC	fatigue/weakness	54	86	0.7	3.6	0.6
1 symptom: lowest TPC	loss of taste	33	98	0.658	1.5	0.2
1 symptom: lowest inflation factor	loss of smell	33	98	0.654	1.6	0.2
2 symptoms: highest sensitivity	cough or headache	72	59	0.655	6.5	1.4
2 symptoms: highest AUROC	loss of smell or fatigue/weakness	64	84	0.742	3.4	0.6
2 symptoms: lowest TPC	loss of taste or loss of smell	39	84 97	0.683	1.7	0.0
2 symptoms: lowest inflation factor	loss of taste or loss of smell	39	97 52	0.683	1.7	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	79	53	0.659	6.8	1.6
3 symptoms: highest AUROC	loss of smell or fever or fatigue/weakness	70	81	0.754	3.6	0.7
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	55	92	0.737	2.4	0.4
3 symptoms: lowest inflation factor	loss of taste or loss of smell or nausea/vomiting	46	92	0.689	2.7	0.4
5 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache or sore throat	86	41	0.632	7.7	2
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia	74	77	0.752	4.1	0.9
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or nausea/vomiting	63	83	0.732	3.6	0.7
5 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea or nausea/vomiting	51	84	0.677	4	0.6
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	87	39	0.632	7.8	2
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	75	74	0.745	4.4	1
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or nausea/vomiting	64	80	0.721	4.1	0.8
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	62	80	0.709	4.1	0.8
7 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or muscle ache/myalgia or headache or sore throat	88	37	0.623	8	2.1
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or nausea/vomiting	76	71	0.734	4.7	1.1
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	66	76	0.71	4.5	0.9
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	66	76	0.71	4.5	0.9

Criteria	Symptoms	sensitivity	specificity	AUROC	трс	inflation
ontoniu	Ct<30	sensitivity	specificity	lience		minution
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	92	29	0.604	11	2.4
4 classic symptoms	Fever or cough or loss of taste or loss of smell	78	73	0.756	5.5	1
4 classic symptoms + fatigue/weakness**	Fever or cough or loss of taste or loss of smell or fatigue/weakness	85	64	0.744	6.5	1.3
4 classic symptoms + fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	86	60	0.733	7	1.4
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or	86	52	0.689	8.3	1.7
4 symptoms: highest AUROC	headache loss of taste or loss of smell or fever or fatigue/weakness	75	81	0.778	4.4	0.8
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath	65	87	0.76	3.5	0.5
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or nausea/vomiting	51	88	0.695	4.1	0.5
1 symptom: highest sensitivity	cough	58	78	0.681	5.9	0.8
1 symptom: highest AUROC	fatigue/weakness	57	86	0.715	4.2	0.6
1 symptom: lowest TPC	loss of taste	35	98	0.667	1.7	0.1
1 symptom: lowest inflation factor	loss of smell	34	98	0.66	1.7	0.1
2 symptoms: highest sensitivity	cough or headache	76	59	0.674	8	1.4
2 symptoms: highest AUROC	loss of smell or fatigue/weakness	67	84	0.756	4	0.6
2 symptoms: lowest TPC	loss of taste or loss of smell	41	97	0.692	1.9	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	41	97	0.692	1.9	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	82	53	0.675	8.5	1.6
3 symptoms: highest AUROC	loss of smell or fever or fatigue/weakness	73	81	0.773	4.3	0.7
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	60	92	0.759	2.7	0.4
3 symptoms: lowest inflation factor	loss of taste or loss of smell or nausea/vomiting	48	92	0.702	3.2	0.4
5 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache or sore throat	88	41	0.645	9.7	2
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia	77	77	0.77	4.9	0.9
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or nausea/vomiting	67	83	0.751	4.3	0.7
5 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea or nausea/vomiting	54	84	0.69	4.8	0.6
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	90	39	0.646	9.8	2.1
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	79	74	0.762	5.3	1
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	66	80	0.731	4.9	0.7
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	66	80	0.731	4.9	0.7
7 symptoms: highest sensitivity	loss of taste or loss of smell or fever or cough or fatigue/weakness or headache or sore throat	91	39	0.647	9.8	2.1
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or nausea/vomiting	79	71	0.751	5.7	1.1
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	69	76	0.729	5.4	0.9
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	69	76	0.729	5.4	0.9
	<i>Ct</i> ≥30					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	83	29	0.559	34.6	2.6
4 classic symptoms	Fever or cough or loss of taste or loss of smell	60	73	0.667	18.5	1

~	It is made available under a CC-BY 4.0 Internatio					. ~ .		
Criteria	Symptoms	sensitivity	specificity	AUROC	TPC	inflation		
4 classic symptoms + fatigue/weakness** 4 classic symptoms +	Fever or cough or loss of taste or loss of smell or fatigue/weakness	71	64	0.675	20.9	1.3		
fatigue/weakness + muscle	Fever or cough or loss of taste or loss of smell							
ache/mylagia**	or fatigue/weakness or muscle ache/myalgia loss of smell or cough or fatigue/weakness or	73	60	0.667	22.2	1.5		
4 symptoms: highest sensitivity	headache loss of taste or loss of smell or	75	52	0.634	26.1	1.8		
4 symptoms: highest AUROC	fatigue/weakness or shortness of breath loss of taste or loss of smell or fever or	60	81	0.704	13.6	0.7		
4 symptoms: lowest TPC	shortness of breath	50	87	0.688	10.9	0.5		
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or nausea/vomiting	41	88	0.644	12.7	0.5		
1 symptom: highest sensitivity	fatigue/weakness	45	86	0.653	13.5	0.5		
1 symptom: highest AUROC	fatigue/weakness	45	86	0.653	13.5	0.5		
1 symptom: lowest TPC	loss of smell	29	98	0.634	3.5	0.1		
1 symptom: lowest inflation factor	loss of taste	28	98	0.63	3.6	0.1		
2 symptoms: highest sensitivity	cough or fatigue/weakness	61	68	0.643	21.8	1.2		
2 symptoms: highest AUROC	loss of smell or fatigue/weakness	55	84	0.698	12	0.6		
2 symptoms: lowest TPC	loss of taste or loss of smell	34	97	0.656	4.3	0.1		
2 symptoms: lowest inflation factor	loss of taste or loss of smell	34	97	0.656	4.3	0.1		
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	70	53	0.612	27.6	1.7		
3 symptoms: highest AUROC	loss of taste or loss of smell or fatigue/weakness	57	84	0.704	12.1	0.6		
3 symptoms: lowest TPC	loss of taste or loss of smell or shortness of breath	45	92	0.682	8.2	0.3		
3 symptoms: lowest inflation factor	loss of taste or loss of smell or fever	42	92	0.672	8.2	0.3		
5 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache or sore throat	78	41	0.593	30.8	2.1		
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or shortness of breath	63	78	0.701	15	0.8		
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or nausea/vomiting	52	83	0.676	13.6	0.6		
5 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea or nausea/vomiting	44	84	0.638	15.3	0.6		
6 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache or shortness of breath or sore throat	79	39	0.591	31.2	2.2		
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	65	74	0.696	16.7	1		
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or nausea/vomiting	53	80	0.665	16	0.8		
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	49	80	0.646	16.8	0.7		
7 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or muscle ache/myalgia or headache or shortness of breath or sore throat	80	37	0.584	31.9	2.3		
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or nausea/vomiting	66	71	0.685	18.2	1.1		
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	55	76	0.657	17.8	0.9		
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	55	76	0.657	17.8	0.9		
Wild type, Ct<30								
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	85	53	0.691	10.3	1.9		
4 classic symptoms	Fever or cough or loss of taste or loss of smell	74	78	0.759	6.1	1		
4 classic symptoms + fatigue/weakness**	Fever or cough or loss of taste or loss of smell or fatigue/weakness	80	72	0.76	6.9	1.2		

	It is made available under a CC-DT 4.0 Internation	Jhar license.				
Criteria	Symptoms	sensitivity	specificity	AUROC	TPC	inflatior
4 classic symptoms +						
fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	81	71	0.76	7.1	1.3
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache	80	68	0.74	7.7	1.4
4 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness	71	87	0.788	4.1	0.6
4 symptoms: lowest TPC	loss of taste or loss of smell or diarrhoea or nausea/vomiting	52	94	0.727	3	0.3
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea	49	94	0.717	3.1	0.3
1 symptom: highest sensitivity	fatigue/weakness	50	91	0.704	4.1	0.5
1 symptom: highest AUROC	fatigue/weakness	50	91	0.704	4.1	0.5
1 symptom: lowest TPC	loss of smell	36	99	0.676	1.5	0.1
1 symptom: lowest inflation factor	loss of smell	36	99	0.676	1.5	0.1
2 symptoms: highest sensitivity	cough or fatigue/weakness	68	75	0.712	7.3	1.1
2 symptoms: highest AUROC	loss of smell or fatigue/weakness	62	90	0.761	3.7	0.5
2 symptoms: lowest TPC	loss of taste or loss of smell	44	98	0.71	1.6	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	44	98	0.71	1.6	0.2
3 symptoms: highest sensitivity	loss of smell or cough or headache	76	72	0.739	7.2	1.2
3 symptoms: highest AUROC	loss of smell or fever or fatigue/weakness	69	87	0.779	4.2	0.6
3 symptoms: lowest TPC	loss of taste or loss of smell or	49	96	0.725	2.4	0.3
	nausea/vomiting					
3 symptoms: lowest inflation factor	loss of taste or loss of smell or diarrhoea loss of smell or fever or cough or	47	96	0.715	2.5	0.3
5 symptoms: highest sensitivity	fatigue/weakness or headache	82	67	0.741	7.9	1.4
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia	74	85	0.792	4.5	0.7
5 symptoms: lowest TPC	loss of taste or loss of smell or abdominal pain or diarrhoea or nausea/vomiting	53	92	0.726	3.5	0.4
5 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea or nausea/vomiting	53	92	0.726	3.5	0.4
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	83	57	0.701	9.7	1.8
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or nausea/vomiting	74	84	0.79	4.7	0.8
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	63	89	0.76	4	0.6
6 symptoms: lowest inflation factor	loss of taste or loss of smell or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	57	89	0.733	4.1	0.5
7 symptoms: highest sensitivity	loss of taste or loss of smell or fever or cough or fatigue/weakness or headache or sore throat	84	57	0.706	9.6	1.8
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or abdominal pain or nausea/vomiting	75	82	0.785	5	0.8
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or muscle ache/myalgia or abdominal pain or diarrhoea or nausea/vomiting	69	86	0.774	4.5	0.7
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	66	86	0.76	4.5	0.7
	Alpha variant compatible, Ct<3	80				
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	95	20	0.578	15	2.7
4 classic symptoms	Fever or cough or loss of taste or loss of smell	79	73	0.761	6.6	1
4 classic symptoms + fatigue/weakness** 4 classic symptoms +	Fever or cough or loss of taste or loss of smell or fatigue/weakness	87	63	0.749	8.2	1.4
fatigue/weakness + muscle	Fever or cough or loss of taste or loss of smell	00	50	0 725	0.0	15
ache/mylagia**	or fatigue/weakness or muscle ache/myalgia cough or fatigue/weakness or headache or	89	58	0.735	8.9	1.5
4 symptoms: highest sensitivity	sore throat	89	36	0.621	13.2	2.2
						58

Criteria	It is made available under a CC-BY 4.0 Internatio Symptoms	sensitivity	specificity	AUROC	ТРС	inflation
4 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness	76	79	0.775	5.6	0.8
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or	63	87	0.749	4.5	0.5
	shortness of breath loss of taste or loss of smell or fever or					
4 symptoms: lowest inflation factor	nausea/vomiting	60	87	0.737	4.6	0.5
1 symptom: highest sensitivity	cough	61	79	0.703	6.7	0.8
1 symptom: highest AUROC	fatigue/weakness	61	84	0.726	5.3	0.6
1 symptom: lowest TPC	loss of taste	31	98	0.645	2.1	0.1
1 symptom: lowest inflation factor 2 symptoms: highest sensitivity	loss of smell cough or fatigue/weakness	28 80	98 67	0.632 0.733	2.2 8	0.1 1.2
2 symptoms: highest AUROC	loss of taste or fatigue/weakness	80 68	83	0.755	°	0.7
2 symptoms: lowest TPC	loss of taste or loss of smell	36	97	0.666	2.5	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	36	97	0.666	2.5	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	86	47	0.664	11.4	1.9
3 symptoms: highest AUROC	loss of taste or fever or fatigue/weakness	74	80	0.772	5.5	0.8
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	57	92	0.744	3.3	0.4
3 symptoms: lowest inflation factor	loss of taste or loss of smell or fever	57	92	0.744	3.3	0.4
5 symptoms: highest sensitivity	loss of taste or cough or fatigue/weakness or	91	35	0.628	13	2.3
5 symptoms: highest AUROC	headache or sore throat loss of taste or loss of smell or fever or	77	76	0.765	6.3	0.9
	fatigue/weakness or shortness of breath loss of taste or loss of smell or fever or	//	70	0.705	0.5	
5 symptoms: lowest TPC	shortness of breath or nausea/vomiting	66	82	0.739	5.6	0.7
5 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or nausea/vomiting	63	82	0.723	5.8	0.7
6 symptoms: highest sensitivity	loss of taste or fever or cough or fatigue/weakness or headache or sore throat	93	33	0.629	13.1	2.3
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	80	71	0.753	7.1	1.1
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or nausea/vomiting	67	77	0.724	6.6	0.8
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	65	78	0.712	6.7	0.8
7 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or muscle ache/myalgia or headache or sore throat	93	30	0.617	13.5	2.4
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or nausea/vomiting	80	68	0.741	7.7	1.2
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	69	74	0.712	7.4	1
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	69	74	0.712	7.4	1
	Delta variant compatible, Ct<30)				
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	95	11	0.529	12.1	2.3
4 classic symptoms	Fever or cough or loss of taste or loss of smell	83	64	0.738	6.1	1
4 classic symptoms + fatigue/weakness** 4 classic symptoms +	Fever or cough or loss of taste or loss of smell or fatigue/weakness	88	53	0.705	7.3	1.3
fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	89	48	0.688	7.8	1.4
4 symptoms: highest sensitivity	loss of smell or cough or headache or sore	90	35	0.627	9.5	1.7
4 symptoms: highest AUROC	throat loss of taste or loss of smell or fever or muscle	74	80	0.772	4.1	0.6
4 symptoms: lowest TPC	ache/myalgia loss of taste or loss of smell or fever or abdominal pain	68	83	0.755	3.9	0.5
	The second se					

	It is made available under a CC-BY 4.0 Internatio					
Criteria	Symptoms	sensitivity	specificity	AUROC	TPC	inflation
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or nausea/vomiting	55	83	0.69	4.6	0.5
1 symptom: highest sensitivity	cough	64	71	0.676	6.3	0.8
1 symptom: highest AUROC	fatigue/weakness	60	81	0.705	4.7	0.6
1 symptom: lowest TPC	loss of smell	39	97	0.682	1.8	0.1
1 symptom: lowest inflation factor	loss of taste	38	97	0.678	1.8	0.1
2 symptoms: highest sensitivity	cough or headache	82	50	0.663	8.1	1.3
2 symptoms: highest AUROC	loss of smell or fever	64	90	0.77	2.8	0.3
2 symptoms: lowest TPC	loss of taste or loss of smell	46	96	0.709	2.1	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	46	96	0.709	2.1	0.2
3 symptoms: highest sensitivity	cough or headache or sore throat	87	36	0.616	9.6	1.7
3 symptoms: highest AUROC	loss of taste or loss of smell or fever	67	89	0.778	2.9	0.4
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	67	89	0.778	2.9	0.4
3 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain	50	89	0.694	3.6	0.4
5 symptoms: highest sensitivity	loss of smell or fever or cough or headache or sore throat	93	33	0.628	9.5	1.7
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia	81	69	0.754	5.4	0.9
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or	70	78	0.742	4.7	0.6
5 symptoms: lowest inflation factor	abdominal pain or nausea/vomiting loss of taste or loss of smell or abdominal pain or diarrhoea or nausea/vomiting	56	78	0.673	5.6	0.6
	loss of smell or fever or cough or	04	26	0.6	10.2	1.0
6 symptoms: highest sensitivity	fatigue/weakness or headache or sore throat	94	26	0.6	10.3	1.9
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	82	65	0.738	6	1
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or muscle ache/myalgia or abdominal pain or nausea/vomiting	76	71	0.737	5.5	0.8
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	71	73	0.719	5.5	0.8
7 symptoms: highest sensitivity	loss of taste or loss of smell or fever or cough or fatigue/weakness or headache or sore throat	94	25	0.598	10.3	1.9
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or abdominal pain or nausea/vomiting	82	62	0.722	6.4	1.1
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or muscle ache/myalgia or shortness of breath or abdominal pain or nausea/vomiting	78	66	0.72	6.1	0.9
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	73	68	0.704	6.2	0.9
	not yet vaccinated					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	89	34	0.613	7.6	2.2
4 classic symptoms	Fever or cough or loss of taste or loss of smell	72	74	0.731	4.2	1
4 classic symptoms + fatigue/weakness**	Fever or cough or loss of taste or loss of smell or fatigue/weakness	80	66	0.731	4.7	1.3
4 classic symptoms + fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	82	63	0.725	5	1.3
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or	82	55	0.685	5.8	1.6
4 symptoms: highest AUROC	headache loss of taste or loss of smell or fever or fatigue/weakness	70	83	0.764	3.2	0.7
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath	60	89	0.744	2.6	0.5
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea	47	89	0.679	3.1	0.5
1 symptom: highest sensitivity	fatigue/weakness	53	88	0.703	3.1	0.5
1 symptom: highest AUROC	fatigue/weakness	53	88	0.703	3.1	0.5

Criteria	Symptoms	sensitivity	specificity	AUDOC	трс	inflation
1 symptom: lowest TPC	loss of taste	32	98	0.654	1.4	0.2
1 symptom: lowest inflation factor	loss of mell	32	98 98	0.648	1.4	0.2
2 symptoms: highest sensitivity	cough or headache	70	61	0.656	5.9	1.4
2 symptoms: highest AUROC	loss of smell or fatigue/weakness	63	87	0.030	2.9	0.6
2 symptoms: lowest TPC	loss of taste or loss of smell	38	98	0.679	1.6	0.0
2 symptoms: lowest inflation factor	loss of taste or loss of smell	38	98	0.679	1.6	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	78	56	0.667	6	1.6
3 symptoms: highest AUROC	loss of smell or fever or fatigue/weakness	68	83	0.758	3.2	0.7
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	54	93	0.734	2.2	0.4
3 symptoms: lowest inflation factor	loss of taste or loss of smell or diarrhoea	43	93	0.681	2.5	0.4
5 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or	85	44	0.642	6.9	1.9
5 symptoms: ingliest sensitivity	headache or sore throat	05	44	0.042	0.9	1.9
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia	73	79	0.761	3.5	0.8
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or	62	85	0.737	3.1	0.6
	shortness of breath or nausea/vomiting loss of taste or loss of smell or abdominal pain	50	07		2.4	0.0
5 symptoms: lowest inflation factor	or diarrhoea or nausea/vomiting	50	86	0.682	3.4	0.6
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	86	42	0.642	6.9	2
	loss of taste or loss of smell or fever or			0.555		0.0
6 symptoms: highest AUROC	fatigue/weakness or muscle ache/myalgia or shortness of breath	74	77	0.757	3.7	0.9
	loss of taste or loss of smell or fever or					
6 symptoms: lowest TPC	shortness of breath <i>or</i> diarrhoea <i>or</i> nausea/vomiting	64	82	0.728	3.5	0.7
	loss of taste or loss of smell or shortness of					
6 symptoms: lowest inflation factor	breath or abdominal pain or diarrhoea or nausea/vomiting	56	83	0.696	3.7	0.7
	loss of taste or loss of smell or fever or cough					
7 symptoms: highest sensitivity	or fatigue/weakness or headache or sore throat	87	42	0.644	6.9	2
	loss of taste or loss of smell or fever or					
7 symptoms: highest AUROC	fatigue/weakness or muscle ache/myalgia or shortness of breath or nausea/vomiting	75	75	0.747	4	1
	loss of taste or loss of smell or fever or					
7 symptoms: lowest TPC	shortness of breath <i>or</i> abdominal pain <i>or</i> diarrhoea <i>or</i> nausea/vomiting	65	79	0.72	3.8	0.8
	loss of taste or loss of smell or fever or					
7 symptoms: lowest inflation factor	shortness of breath <i>or</i> abdominal pain <i>or</i> diarrhoea <i>or</i> nausea/vomiting	65	79	0.72	3.8	0.8
	≥ 21 days from 1st vaccine, <0 days from	2nd vaccine				
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	2 <i>nu vuccine</i> 96	15	0.555	35.2	3
4 classic symptoms	Fever or cough or loss of taste or loss of smell	90 78	13 73	0.355	14.2	1
4 classic symptoms +	Fever or cough or loss of taste or loss of smell	10	15	0.131	17.2	1
fatigue/weakness**	or fatigue/weakness	88	60	0.741	18.5	1.5
4 classic symptoms + fatigue/weakness + muscle	Fever or cough or loss of taste or loss of smell					
ache/mylagia**	or fatigue/weakness or muscle ache/myalgia	90	54	0.72	20.7	1.7
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache	90	42	0.662	25.7	2.1
4 symptoms: highest AUROC	loss of taste or loss of smell or fever or cough	78	73	0.757	14.2	1
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or	53	86	0.698	11	0.5
	nausea/vomiting loss of taste or loss of smell or fever or					
4 symptoms: lowest inflation factor	nausea/vomiting	53	86	0.698	11	0.5
1 symptom: highest sensitivity	cough	63	79	0.71	13.7	0.8
1 symptom: highest AUROC	cough	63	79	0.71	13.7	0.8
1 symptom: lowest TPC	loss of taste	38	98	0.68	3.3	0.1
1 symptom: lowest inflation factor	loss of taste	38	98	0.68	3.3	0.1
2 symptoms: highest sensitivity	cough or fatigue/weakness	80	64	0.718	18.4	1.3
2 symptoms: highest AUROC	loss of taste or cough	72	78	0.75	12.9	0.8

Criteria	It is made available under a CC-BY 4.0 Internation	sensitivity	specificity	AUROC	трс	inflation
2 symptoms: lowest TPC	loss of taste or loss of smell	44	96	0.701	4.2	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	44	96	0.701	4.2	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	87	44	0.651	26.1	2
3 symptoms: highest AUROC	loss of taste or loss of smell or cough	75	77	0.757	13	0.9
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	52	92	0.717	7.3	0.3
3 symptoms: lowest inflation factor	loss of taste or loss of smell or fever	52	92	0.717	7.3	0.3
5 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or	92	32	0.622	29.4	2.4
	headache or sore throat loss of taste or loss of smell or fever or cough					
5 symptoms: highest AUROC	or fatigue/weakness	88	60	0.741	18.5	1.5
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or abdominal pain or nausea/vomiting	55	81	0.679	14.3	0.7
5 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or	55	81	0.679	14.3	0.7
	abdominal pain or nausea/vomiting loss of smell or cough or fatigue/weakness or		27		20.0	
6 symptoms: highest sensitivity	headache or sore throat or diarrhoea	94	27	0.605	30.9	2.6
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or cough or fatigue/weakness or shortness of breath	90	56	0.73	19.8	1.6
	loss of taste or loss of smell or fever or	50	76	0 (71	16.0	0.0
6 symptoms: lowest TPC	abdominal pain <i>or</i> diarrhoea <i>or</i> nausea/vomiting	58	76	0.671	16.9	0.9
	loss of taste or loss of smell or fever or	50	76	0 (71	16.0	0.0
6 symptoms: lowest inflation factor	abdominal pain <i>or</i> diarrhoea <i>or</i> nausea/vomiting	58	76	0.671	16.9	0.9
7 symptoms, highost consitivity	loss of smell or cough or fatigue/weakness or muscle ache/myalgia or headache or sore	95	23	0.59	32.3	2.8
7 symptoms: highest sensitivity	throat or diarrhoea	95	25	0.39	32.3	2.8
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or cough or fatigue/weakness or shortness of breath or	90	52	0.714	21.3	1.7
7 symptoms: inglest AUKOC	abdominal pain	90	32	0.714	21.5	1.7
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or fatigue/weakness or abdominal pain or	77	64	0.705	19.1	1.3
7 symptoms: lowest TFC	diarrhoea or nausea/vomiting	11	04	0.703	19.1	1.5
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or	63	70	0.662	19.6	1.1
7 symptoms: lowest milation factor	diarrhoea or nausea/vomiting	05	70	0.002	17.0	1.1
	≥ 14 days from 2nd vaccine					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	95	12	0.537	16.3	2.6
4 classic symptoms	Fever or cough or loss of taste or loss of smell	82	69	0.753	7.3	1
4 classic symptoms + fatigue/weakness**	Fever or cough or loss of taste or loss of smell or fatigue/weakness	88	56	0.722	9.3	1.4
4 classic symptoms +		00	20	0.722	7.5	1.1
fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	90	50	0.702	10.2	1.5
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or	91	43	0.669	11.4	1.7
	headache loss of taste or loss of smell or fever or muscle					
4 symptoms: highest AUROC	ache/myalgia	73	80	0.763	5.6	0.7
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or nausea/vomiting	66	85	0.752	4.9	0.5
4 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or nausea/vomiting	66	85	0.752	4.9	0.5
1 symptom: highest sensitivity	cough	64	75	0.696	7.5	0.8
1 symptom: highest AUROC	fatigue/weakness	60	80	0.7	6.6	0.7
1 symptom: lowest TPC	loss of smell	41	97	0.692	2.1	0.1
1 symptom: lowest inflation factor	loss of taste	40	97	0.684	2.2	0.1
2 symptoms: highest sensitivity	cough or headache	81	54	0.677	10.3	1.4
2 symptoms: highest AUROC	loss of smell or fever	60	92	0.759	3.2	0.3
2 symptoms: lowest TPC	loss of taste or loss of smell	47	96	0.714	2.5	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	47	96	0.714	2.5	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	87	44	0.657	11.6	1.7
3 symptoms: highest AUROC	loss of taste or loss of smell or fever	63	91	0.769	3.5	0.4

Criteria	It is made available under a CC-BY 4.0 Internation	sensitivity	specificity	AUDOC	трс	inflation
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	63	91	0.769	3.5	0.4
3 symptoms: lowest inflation factor	loss of taste or loss of smell or fever	63	91	0.769	3.5	0.4
	loss of taske of loss of smell or jever					
5 symptoms: highest sensitivity	headache or sore throat	92	32	0.62	13.3	2
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or muscle ache/myalgia or nausea/vomiting	74	75	0.745	6.6	0.8
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or	67	80	0.734	6	0.7
	abdominal pain or nausea/vomiting loss of taste or loss of smell or fever or	6 7	00	0.724	6	0.7
5 symptoms: lowest inflation factor	abdominal pain or nausea/vomiting	67	80	0.734	6	0.7
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	93	30	0.618	13.4	2.1
Committee the high set AUDOC	loss of taste or loss of smell or fever or	79	66	0.729	8	1.1
6 symptoms: highest AUROC	fatigue/weakness or abdominal pain or nausea/vomiting	19	00	0.729	0	1.1
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or	68	74	0.707	7.4	0.8
o symptoms: lowest TPC	nausea/vomiting	08	74	0.707	7.4	0.8
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or	68	74	0.707	7.4	0.8
o symptoms: towest initiation factor	nausea/vomiting	08	/4	0.707	7.4	0.8
7 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or muscle ache/myalgia or	94	26	0.598	14.1	2.2
7 symptoms, inglest sensitivity	headache or sore throat	74	20	0.598	14.1	2.2
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or	82	61	0.713	9	1.2
7 symptoms. inglest AOROC	abdominal pain or nausea/vomiting	02	01	0.715)	1.2
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or muscle ache/myalgia or abdominal pain or diarrhoea	75	65	0.701	8.7	1.1
7 symptoms. Towest 11 C	or nausea/vomiting	15	05	0.701	0.7	1.1
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or	72	66	0.69	8.8	1.1
7 symptoms. Towest milation factor	diarrhoea or nausea/vomiting	12	00	0.07	0.0	1.1
	2-5 years					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	83	21	0.521	19.5	1.2
4 classic symptoms	Fever or cough or loss of taste or loss of smell	68	35	0.516	19.6	1
4 classic symptoms + fatigue/weakness**	Fever or cough or loss of taste or loss of smell	73	33	0.531	18.8	1
4 classic symptoms +	or fatigue/weakness	15	33	0.551	10.0	1
fatigue/weakness + muscle	Fever or cough or loss of taste or loss of smell	72	22	0.520	19.0	1
ache/mylagia**	or fatigue/weakness or muscle ache/myalgia fever or cough or fatigue/weakness or	73 76	33	0.529	18.9	1
4 symptoms: highest sensitivity	diarrhoea	/0	31	0.536	18.6	1.1
4 symptoms: highest AUROC	loss of taste or fever or fatigue/weakness or diarrhoea	59	72	0.656	10.1	0.4
4 symptoms: lowest TPC	loss of taste or loss of smell or muscle ache/myalgia or headache	24	94	0.588	6.2	0.1
4 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle	14	96	0.553	6.3	0.1
	ache/myalgia <i>or</i> shortness of breath					
1 symptom: highest sensitivity	fever	42	80	0.606	10.6	0.3
1 symptom: highest AUROC	fever	42	80	0.606	10.6	0.3
1 symptom: lowest TPC	loss of taste	8	99	0.539	2.4	0
1 symptom: lowest inflation factor 2 symptoms: highest sensitivity	loss of smell fever or cough	6 66	99 36	0.524 0.51	3.4 19.9	0
2 symptoms: highest AUROC	fever or cougn fever or fatigue/weakness	53	30 76	0.51	9.8	0.4
2 symptoms: lowest TPC	loss of taste or muscle ache/myalgia	14	98	0.561	3.5	0.4
2 symptoms: lowest inflation factor	loss of taste or loss of smell	8	99 99	0.536	3.7	0
3 symptoms: highest sensitivity	fever or cough or fatigue/weakness	72	34	0.530	18.8	1
3 symptoms: highest AUROC	loss of taste or fever or fatigue/weakness	55	76	0.654	9.6	0.4
3 symptoms: lowest TPC	loss of taste or loss of smell or muscle	14	98	0.558	4.2	0.4
	ache/myalgia		90	0.558	4.2	0
3 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia	14	98	0.558	4.2	0

Criteria	It is made available under a CC-BY 4.0 Internation Symptoms	sensitivity	specificity	AUPOC	трс	inflation
	<i>fever or cough or fatigue/weakness or</i>	2				
5 symptoms: highest sensitivity	headache or diarrhoea	79	30	0.543	18.4	1.1
5 symptoms: highest sensitivity	fever or cough or fatigue/weakness or sore throat or diarrhoea	79	26	0.526	19.2	1.1
5 symptoms: highest sensitivity	fever or cough or headache or sore throat or diarrhoea	79	26	0.526	19.2	1.1
5 symptoms: highest AUROC	loss of taste or fever or fatigue/weakness or headache or diarrhoea	62	70	0.659	10.4	0.5
	loss of taste or loss of smell or					
5 symptoms: lowest TPC	fatigue/weakness or muscle ache/myalgia or headache	38	88	0.632	7	0.2
5 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or headache or shortness of breath	24	92	0.583	7.2	0.1
6 symptoms: highest sensitivity	fever or cough or fatigue/weakness or headache or sore throat or diarrhoea	82	25	0.534	18.9	1.2
6 symptoms: highest AUROC	loss of taste or fever or fatigue/weakness or	62	69	0.658	10.6	0.5
· -j	headache or shortness of breath or diarrhoea loss of taste or loss of smell or					
6 symptoms: lowest TPC	fatigue/weakness or muscle ache/myalgia or headache or shortness of breath	39	87	0.629	7.5	0.2
6 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or headache or shortness of breath or abdominal pain	31	88	0.593	8.6	0.2
7 symptoms: highest sensitivity	loss of taste or fever or cough or fatigue/weakness or headache or sore throat or diarrhoea	82	25	0.537	18.7	1.2
7 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat or diarrhoea	82	25	0.535	18.8	1.2
7 symptoms: highest sensitivity	fever or cough or fatigue/weakness or headache or sore throat or abdominal pain or diarrhoea	82	23	0.528	19.1	1.2
7 symptoms: highest sensitivity	fever or cough or fatigue/weakness or headache or sore throat or diarrhoea or nausea/vomiting	82	23	0.527	19.2	1.2
7 symptoms: highest AUROC	loss of taste or fever or fatigue/weakness or muscle ache/myalgia or headache or shortness of breath or diarrhoea	62	69	0.656	10.7	0.5
7 symptoms: lowest TPC	loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia or headache or shortness of breath or abdominal pain	43	84	0.633	8.3	0.3
7 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or headache or shortness of breath or abdominal pain or diarrhoea	36	85	0.604	9.3	0.3
	6-10 years					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	82	22	0.523	12.7	1.8
4 classic symptoms	Fever or cough or loss of taste or loss of smell	60	59	0.593	9.5	1
4 classic symptoms + fatigue/weakness**	Fever or cough or loss of taste or loss of smell or fatigue/weakness	67	55	0.61	9.3	1.1
4 classic symptoms +	_	07	55	0.01	1.5	1.1
fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	68	54	0.606	9.5	1.1
4 symptoms: highest sensitivity	fever or cough or fatigue/weakness or	74	46	0.603	9.9	1.1
4 symptoms: highest AUROC	headache loss of smell or fever or fatigue/weakness or		71			0.7
4 symptoms: nighest AUROC 4 symptoms: lowest TPC	headache loss of taste or loss of smell or muscle	65 25	71 94	0.679 0.592	6.5 4.2	0.7
	ache/myalgia or shortness of breath loss of taste or loss of smell or muscle					
4 symptoms: lowest inflation factor	ache/myalgia or shortness of breath	25	94	0.592	4.2	0.2
1 symptom: highest sensitivity	headache	42	83	0.625	5.9	0.4
1 symptom: highest AUROC	headache	42	83	0.625	5.9	0.4
1 symptom: lowest TPC	loss of taste	10	99	0.547	2.1	0
1 symptom: lowest inflation factor	loss of taste	10	99 54	0.547	2.1	0
2 symptoms: highest sensitivity	cough or headache	62	54	0.58	10.2	1.1

	It is made available under a CC-BY 4.0 Internati					
Criteria	Symptoms	sensitivity	specificity			
2 symptoms: highest AUROC	fever or headache	55	75	0.652	6.5	0.6
2 symptoms: lowest TPC	loss of taste or loss of smell	14	98	0.56	2.6	0.1
2 symptoms: lowest inflation factor	loss of taste or loss of smell	14	98	0.56	2.6	0.1
3 symptoms: highest sensitivity	fever or cough or headache	71	49	0.599	9.9	1.2
3 symptoms: highest AUROC	loss of smell or fever or headache	60	75	0.671	6.3	0.7
3 symptoms: lowest TPC	loss of taste or loss of smell or shortness of breath	16	97	0.566	3.5	0.1
3 symptoms: lowest inflation factor	loss of taste or loss of smell or shortness of breath	16	97	0.566	3.5	0.1
5 symptoms: highest sensitivity	fever or cough or fatigue/weakness or headache or sore throat	77	33	0.552	11.7	1.6
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or headache	65	71	0.679	6.5	0.7
5 symptoms: lowest TPC	loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia or shortness of breath	39	88	0.635	4.9	0.3
5 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or shortness of breath or diarrhoea	29	89	0.59	5.7	0.3
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	79	33	0.561	11.4	1.6
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or headache	66	69	0.676	6.7	0.8
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	53	80	0.663	5.7	0.5
6 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or shortness of breath or diarrhoea or nausea/vomiting	35	83	0.59	6.9	0.4
7 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat or abdominal pain	80	29	0.544	12	1.7
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or headache or shortness of breath	66	69	0.673	6.8	0.8
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or diarrhoea	54	76	0.651	6.4	0.6
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia or shortness of breath or diarrhoea or nausea/vomiting	45	79	0.619	6.8	0.5
	11-15					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	89	22	0.556	6.8	2.1
4 classic symptoms	Fever or cough or loss of taste or loss of smell	68	67	0.678	4.2	1
4 classic symptoms + fatigue/weakness** 4 classic symptoms +	Fever or cough or loss of taste or loss of smell or fatigue/weakness	76	61	0.685	4.4	1.2
fatigue/weakness + muscle	Fever or cough or loss of taste or loss of smell	77	50	0 201	15	1.2
ache/mylagia**	or fatigue/weakness or muscle ache/myalgia loss of smell or cough or headache or sore	77	59	0.681	4.5	1.2
4 symptoms: highest sensitivity	loss of taste or loss of smell or fever or	81	36	0.585	6.2	1.8
4 symptoms: highest AUROC 4 symptoms: lowest TPC	fatigue/weakness loss of taste or loss of smell or muscle	66 49	82 90	0.738 0.698	2.9 2.3	0.7 0.4
4 symptoms: lowest inflation factor	ache/myalgia or shortness of breath loss of taste or loss of smell or shortness of	49	90	0.661	2.3	0.4
1 symptom: highest sensitivity	breath or diarrhoea headache	50	73	0.617	4.6	0.8
1 symptom: highest AUROC	fatigue/weakness	40	88	0.642	4.0 2.9	0.8
			88 98		2.9 1.5	0.4
1 symptom: lowest TPC	loss of taste	24		0.608		
1 symptom: lowest inflation factor	shortness of breath	12	98	0.55	2.3	0.1
2 symptoms: highest sensitivity	cough or headache	66 54	52	0.59	5.8	1.4
2 symptoms: highest AUROC	loss of smell or fatigue/weakness	54	87	0.707	2.6	0.5

	It is made available under a CC-BY 4.0 Internation		• 0* •		mp ~	• <i>(</i> = .•
Criteria	Symptoms	sensitivity	specificity			
2 symptoms: lowest TPC	loss of taste or loss of smell	32	97	0.645	1.7	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	32	97	0.645	1.7	0.2
3 symptoms: highest sensitivity	loss of smell or cough or headache	74	51	0.626	5.4	1.4
3 symptoms: highest AUROC	loss of smell or fever or fatigue/weakness	64	82	0.731	2.8	0.6
3 symptoms: lowest TPC	loss of taste or loss of smell or shortness of breath	38	95	0.666	1.9	0.3
3 symptoms: lowest inflation factor	loss of taste or loss of smell or shortness of breath	38	95	0.666	1.9	0.3
5 symptoms: highest sensitivity	loss of smell or fever or cough or headache or sore throat	84	34	0.591	6.2	1.8
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or shortness of breath	68	80	0.74	2.9	0.7
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or muscle ache/myalgia or shortness of breath	61	84	0.729	2.7	0.6
5 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or shortness of breath or diarrhoea	51	87	0.689	2.7	0.5
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	87	31	0.588	6.3	1.9
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	69	78	0.737	3.1	0.8
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or muscle ache/myalgia or shortness of breath or diarrhoea	62	82	0.718	3	0.6
6 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or shortness of breath or abdominal pain or diarrhoea	53	82	0.674	3.3	0.6
7 symptoms: highest sensitivity	loss of taste or loss of smell or fever or cough or fatigue/weakness or headache or sore throat	88	31	0.591	6.3	1.9
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or diarrhoea	70	76	0.726	3.3	0.8
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or diarrhoea	70	76	0.726	3.3	0.8
7 symptoms: lowest inflation factor	loss of taste or loss of smell or muscle ache/myalgia or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	56	78	0.667	3.7	0.7
	16-44					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	90	27	0.586	7.2	2.3
4 classic symptoms	Fever or cough or loss of taste or loss of smell	76	<u>-</u> , 74	0.746	3.7	1
4 classic symptoms + fatigue/weakness** 4 classic symptoms +	Fever or cough or loss of taste or loss of smell or fatigue/weakness	83	64	0.735	4.3	1.3
fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	85	61	0.728	4.5	1.4
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or	85	49	0.669	5.6	1.7
4 symptoms: highest AUROC	headache loss of taste or loss of smell or fever or muscle ache/myalgia	69	86	0.776	2.5	0.6
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath	65	89	0.769	2.3	0.5
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea	52	89	0.704	2.6	0.5
1 symptom: highest sensitivity	fatigue/weakness	56	85	0.704	3	0.6
1 symptom: highest AUROC	fatigue/weakness	56	85	0.704	3	0.6
1 symptom: lowest TPC	loss of smell	39	98	0.688	1.4	0.2
1 symptom: lowest inflation factor	diarrhoea	11	95	0.528	4.6	0.2
2 symptoms: highest sensitivity	cough or headache	72	56	0.643	5.6	1.5
2 symptoms: highest AUROC	loss of smell or fatigue/weakness	68	84	0.759	2.8	0.7
2 symptoms: lowest TPC	loss of taste or loss of smell	45	97	0.713	1.5	0.2
2 symptoms, towest 11 C	ioss of insie of ioss of smell	75		0.715	1.5	0.2

	It is made available under a CC-BY 4.0 Internation					
Criteria	Symptoms	sensitivity	specificity	AUROC		inflation
2 symptoms: lowest inflation factor	loss of taste or loss of smell	45	97	0.713	1.5	0.2
3 symptoms: highest sensitivity	loss of smell or cough or headache	80	55	0.679	5.3	1.5
3 symptoms: highest AUROC	loss of smell or fever or fatigue/weakness	73	81	0.77	3	0.8
3 symptoms: lowest TPC	loss of taste or loss of smell or shortness of breath	54	93	0.736	1.9	0.4
3 symptoms: lowest inflation factor	loss of taste or loss of smell or shortness of breath	54	93	0.736	1.9	0.4
5 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache or sore throat	87	36	0.615	6.6	2.1
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or muscle ache/myalgia or shortness of breath	72	83	0.776	2.8	0.7
5 symptoms: lowest TPC	loss of taste or loss of smell or fever shortness of breath or diarrhoea	66	85	0.756	2.7	0.6
5 symptoms: lowest inflation factor	loss of taste or loss of smell or shortness of breath or abdominal pain or diarrhoea	58	86	0.719	2.9	0.6
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	88	35	0.613	6.7	2.1
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	78	75	0.768	3.4	1
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea loss of taste or loss of smell or shortness of	67	82	0.745	3.1	0.7
6 symptoms: lowest inflation factor	breath or abdominal pain or diarrhoea or nausea/vomiting loss of taste or loss of smell or fever or cough	60	82	0.713	3.2	0.7
7 symptoms: highest sensitivity	or fatigue/weakness or headache or sore throat loss of taste or loss of smell or fever or	89	34	0.615	6.7	2.1
7 symptoms: highest AUROC	fatigue/weakness or muscle ache/myalgia or shortness of breath or abdominal pain loss of taste or loss of smell or fever or	79	72	0.756	3.7	1
7 symptoms: lowest TPC	shortness of breath or abdominal pain or diarrhoea or nausea/vomiting loss of taste or loss of smell or fever or	68	79	0.736	3.4	0.8
7 symptoms: lowest inflation factor	shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	68	79	0.736	3.4	0.8
	45-64					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	91	31	0.611	8.2	2.5
4 classic symptoms	Fever or cough or loss of taste or loss of smell	76	77	0.762	3.9	1
4 classic symptoms + fatigue/weakness** 4 classic symptoms +	Fever or cough or loss of taste or loss of smell or fatigue/weakness	84	67	0.754	4.7	1.3
fatigue/weakness + muscle ache/mylagia**	Fever or cough or loss of taste or loss of smell or fatigue/weakness or muscle ache/myalgia	85	63	0.742	5.1	1.5
4 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache	86	53	0.694	6.2	1.8
4 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness	74	81	0.773	3.4	0.8
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or nausea/vomiting	60	89	0.744	2.8	0.6
4 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or nausea/vomiting	52	88	0.698	3.2	0.6
1 symptom: highest sensitivity	fatigue/weakness	60	85	0.726	3.3	0.7
1 symptom: highest AUROC	fatigue/weakness	60	85	0.726	3.3	0.7
1 symptom: lowest TPC	loss of taste	36	98	0.672	1.5	0.2
1 symptom: lowest inflation factor	loss of smell	33	98	0.658	1.5	0.2
2 symptoms: highest sensitivity	cough or fatigue/weakness	77	70	0.736	4.7	1.2
2 symptoms: highest AUROC	loss of taste or fatigue/weakness	68	84	0.759	3.2	0.7
2 symptoms: lowest TPC	loss of taste or loss of smell	41	97	0.692	1.7	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	41	97	0.692	1.7	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	83	54	0.685	6.3	1.7
3 symptoms: highest AUROC	loss of taste or fever or fatigue/weakness	72	82	0.77	3.4	0.8

Criteria	It is made available under a CC-BY 4.0 Internation Symptoms	sensitivity	specificity	AUROC	трс	inflation
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	57	93	0.749	2.2	0.4
	loss of taste or loss of smell or	48	92	0.702	2.6	0.4
3 symptoms: lowest inflation factor	nausea/vomiting	40	92	0.702	2.0	0.4
5 symptoms: highest sensitivity	loss of smell or cough or fatigue/weakness or headache or sore throat	88	42	0.651	7.2	2.1
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or shortness of breath	76	78	0.767	3.8	1
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or nausea/vomiting	66	84	0.75	3.3	0.7
5 symptoms: lowest inflation factor	loss of taste or loss of smell or abdominal pain or diarrhoea or nausea/vomiting	55	84	0.694	3.7	0.7
6 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or sore throat	89	41	0.65	7.3	2.2
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath	78	74	0.759	4.2	1.1
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or nausea/vomiting	67	81	0.74	3.7	0.8
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	64	81	0.726	3.8	0.8
7 symptoms: highest sensitivity	loss of smell or fever or cough or fatigue/weakness or headache or shortness of breath or sore throat	89	40	0.646	7.4	2.2
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or fatigue/weakness or muscle ache/myalgia or shortness of breath or nausea/vomiting	79	71	0.75	4.5	1.2
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	69	77	0.729	4.1	1
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	69	77	0.729	4.1	1
	65+					
Any of the 12 elicited symptoms	Any one of the 12 elicited symptoms	88	32	0.597	14.5	2.6
4 classic symptoms	Fever or cough or loss of taste or loss of smell	69	76	0.725	7.1	1
4 classic symptoms + fatigue/weakness** 4 classic symptoms + fatigue/weakness + muscle	Fever or cough or loss of taste or loss of smell or fatigue/weakness Fever or cough or loss of taste or loss of smell	79	65	0.718	8.7	1.4
ache/mylagia**	or fatigue/weakness or muscle ache/myalgia loss of smell or cough or fatigue/weakness or	80	60	0.701	9.6	1.6
4 symptoms: highest sensitivity	headache	82	56	0.689	10.3	1.7
4 symptoms: highest AUROC	loss of taste or loss of smell or fever or cough	69	76	0.725	7.1	1
4 symptoms: lowest TPC	loss of taste or loss of smell or fever or nausea/vomiting	47	90	0.684	4.7	0.5
4 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or nausea/vomiting	47	90	0.684	4.7	0.5
1 symptom: highest sensitivity	cough	56	80	0.677	7.3	0.8
1 symptom: highest AUROC	fatigue/weakness	53	84	0.685	6.2	0.7
1 symptom: lowest TPC	loss of taste	26	98	0.618	2.3	0.1
1 symptom: lowest inflation factor	loss of smell	21	98	0.594	2.6	0.1
2 symptoms: highest sensitivity	cough or fatigue/weakness	73	68	0.706	8.5	1.3
2 symptoms: highest AUROC	loss of taste or cough	64	79	0.712	6.8	0.9
2 symptoms: lowest TPC	loss of taste or loss of smell	29	97	0.631	2.8	0.2
2 symptoms: lowest inflation factor	loss of taste or loss of smell	29	97	0.631	2.8	0.2
3 symptoms: highest sensitivity	cough or fatigue/weakness or headache	79	57	0.681	10.3	1.7
3 symptoms: highest AUROC	loss of taste or fever or cough	68	76	0.723	7	1
3 symptoms: lowest TPC	loss of taste or loss of smell or fever	42	94	0.68	3.5	0.3
3 symptoms: lowest inflation factor	loss of taste or loss of smell or fever	42	94	0.68	3.5	0.3
	loss of smell or cough or fatigue/weakness or					

per	peluity.
It is made available under a	CC-BY 4.0 International license .

Criteria	It is made available under a CC-BY 4.0 Internation	sensitivity	specificity	AUROC	трс	inflation
Cinterna	, , , , , , , , , , , , , , , , , , ,	sensitivity	specificity	AUNOC	ne	milation
5 symptoms: highest AUROC	loss of taste or loss of smell or fever or cough or fatigue/weakness	79	65	0.718	8.7	1.4
5 symptoms: lowest TPC	loss of taste or loss of smell or fever or abdominal pain or nausea/vomiting	49	85	0.67	6.2	0.6
5 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or nausea/vomiting	49	85	0.67	6.2	0.6
6 symptoms: highest sensitivity	loss of taste or cough or fatigue/weakness or muscle ache/myalgia or headache or sore throat	85	44	0.643	12.4	2.1
6 symptoms: highest AUROC	loss of taste or loss of smell or fever or cough or fatigue/weakness or nausea/vomiting	79	62	0.708	9.2	1.5
6 symptoms: lowest TPC	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	51	80	0.658	7.6	0.8
6 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or abdominal pain or diarrhoea or nausea/vomiting	51	80	0.658	7.6	0.8
7 symptoms: highest sensitivity	loss of taste or cough or fatigue/weakness or muscle ache/myalgia or headache or sore throat or diarrhoea	86	39	0.625	13.2	2.3
7 symptoms: highest AUROC	loss of taste or loss of smell or fever or cough or fatigue/weakness or shortness of breath or nausea/vomiting	81	58	0.695	9.9	1.6
7 symptoms: lowest TPC	loss of taste or loss of smell or fever or fatigue/weakness or abdominal pain or diarrhoea or nausea/vomiting	67	70	0.685	8.7	1.2
7 symptoms: lowest inflation factor	loss of taste or loss of smell or fever or shortness of breath or abdominal pain or diarrhoea or nausea/vomiting	58	73	0.654	9.1	1.1

Note: question about fatigue/weakness asked as "weakness/tiredness" to participants. Classic symptoms italicised, other symptoms in bold.

*TPC=1/PPV

**See Table S5

Table S5 Sensitivity, test per case (TPC), AUROC and inflation factor for various symptom combinations in different groups of positive episodes vs test-negative visits

3 A

Л						
Subgroup	classic (4)	classic or fatigue/weakness (5)	classic or muscle ache/myalgia (5)	classic or headache (5)	classic or diarrhoea (5)	any of the 12 named symptoms (12)
All positives	74%/4.6/0.734/1	81%/5.3/0.727/1.3	78%/5.1/0.726/1.2	82%/6.3/0.686/1.5	75%/5.1/0.717/1.1	90%/8.7/0.593/2.3
Ct<30	78%/5.5/0.756/1	85%/6.5/0.744/1.3	82%/6.2/0.747/1.2	86%/7.8/0.704/1.6	79%/6.2/0.738/1.1	92%/11/0.604/2.4
Ct≥30	60%/18.5/0.667/ 1	71%/20.9/0.675/1.3	66%/20.6/0.663/1.2	71%/25.7/0.63/1.6	62%/21/0.653/1.2	83%/34.6/0.559/2.6
Wild type, Ct<30	74%/6.1/0.759/1	80%/6.9/0.76/1.2	78%/6.5/0.763/1.1	80%/7.3/0.75/1.3	75%/6.5/0.753/1.1	85%/10.3/0.691/1.9
Alpha variant compatible, Ct<30	700/ 16 610 761 11	970/ /9 2/0 740/1 4	940/ 17 7/0 75/1 2	970/ /10 6/0 694/1 9	900/ /7 7/0 741/1 2	050/ /15/0 579/0 7
Delta variant compatible,	79%/6.6/0.761/1	87%/8.2/0.749/1.4	84%/7.7/0.75/1.2	87%/10.6/0.684/1.8	80%/7.7/0.741/1.2	95%/15/0.578/2.7
Ct<30	83%/6.1/0.738/1	88%/7.3/0.705/1.3	86%/6.9/0.717/1.2	90%/8.1/0.679/1.4	84%/7/0.705/1.2	95%/12.1/0.529/2.3
Not yet vaccinated	72%/4.2/0.731/1	80%/4.7/0.731/1.3	77%/4.5/0.729/1.2	81%/5.7/0.691/1.5	74%/4.6/0.719/1.1	89%/7.6/0.613/2.2
≥21 days from 1st vaccine, <0 days from 2nd vaccine	78%/14.2/0.757/ 1	88%/18.5/0.741/1.5	83%/18.1/0.73/1.3	85%/24/0.672/1.8	81%/17.2/0.735/1.2	96%/35.2/0.555/3
≥14 days from 2nd vaccine	82%/7.3/0.753/1	88%/9.3/0.722/1.4	86%/8.7/0.731/1.3	88%/10.4/0.692/1.5	83%/8.9/0.716/1.2	95%/16.3/0.537/2.6
2-5y	68%/19.6/0.516/ 1	73%/18.8/0.531/1	68%/19.6/0.516/1	72%/18.9/0.529/1	72%/19.3/0.523/1	83%/19.5/0.521/1.2
6-10y	60%/9.5/0.593/1	67%/9.3/0.61/1.1	62%/9.6/0.593/1	74%/9.7/0.611/1.3	62%/10/0.583/1.1	82%/12.7/0.523/1.8
11-15y	68%/4.2/0.678/1	76%/4.4/0.685/1.2	72%/4.3/0.679/1.1	80%/5.3/0.639/1.5	69%/4.4/0.668/1.1	89%/6.8/0.556/2.1
16-44y	76%/3.7/0.746/1	83%/4.3/0.735/1.3	80%/4/0.743/1.2	84%/5.3/0.681/1.6	77%/4/0.732/1.1	90%/7.2/0.586/2.3
45-64y	76%/3.9/0.762/1	84%/4.7/0.754/1.3	81%/4.6/0.752/1.2	83%/5.9/0.702/1.6	77%/4.5/0.744/1.2	91%/8.2/0.611/2.5
65y+	69%/7.1/0.725/1	79%/8.7/0.718/1.4	74%/8.6/0.707/1.3	76%/9.5/0.694/1.5	71%/8.5/0.703/1.2	88%/14.5/0.597/2.6
26Apr2020-30Aug2020	44%/37.9/0.629/ 1	53%/45.2/0.635/1.5	48%/43.3/0.628/1.3	49%/51.7/0.609/1.5	44%/44.4/0.613/1.2	66%/70/0.578/2.8
1Sep2020-16Nov2020	68%/4.7/0.724/1	74%/5.1/0.731/1.2	72%/4.9/0.73/1.1	75%/5.4/0.719/1.3	69%/4.9/0.72/1.1	81%/7.2/0.671/1.8
17Nov2020-28Feb2021	73%/3.2/0.739/1	82%/3.7/0.737/1.3	78%/3.6/0.731/1.2	83%/4.7/0.671/1.7	75%/3.6/0.72/1.2	92%/6.2/0.577/2.5
1Mar2021-16May2021	76%/16.5/0.733/ 1	83%/21.4/0.705/1.4	79%/20.1/0.709/1.3	82%/27.1/0.646/1.8	77%/19.4/0.71/1.2	92%/38.4/0.534/2.8
17May2021-17Jul2021	82%/5/0.733/1	88%/6/0.702/1.3	85%/5.6/0.712/1.2	89%/6.6/0.673/1.4	83%/5.8/0.701/1.2	94%/9.7/0.526/2.2

4 Note: For any number of symptoms, the combinations achieving the highest sensitivity and highest AUROC are shown in **bold**, and optimizing both in grey

5 shading and bold, excluding the combination of any of the 12 named symptoms, given they achieve the highest sensitivity by definition

~	
h	

В

All positives 76%/4.9/0.729/1.1 79%/6.1/0.687/1.4 75%/5.1/0.718/1.1 75%/5/0.722/1.1 C<30	Subgroup	classic or shortness of breath (5)	classic or sore throat (5)	classic or abdominal pain (5)	classic or nausea/vomiting (5)
Ct≥30 64%/19.30.672/1.1 66%/25.5/0.624/1.5 62%/20.60.655/1.1 75%/64/0.757/1.1 Wild type, Ct<30	All positives	76%/4.9/0.729/1.1	79%/6.1/0.687/1.4	75%/5.1/0.718/1.1	75%/5/0.722/1.1
Wild type, Ct<30	Ct<30	80%/5.9/0.749/1.1	83%/7.5/0.708/1.4	79%/6.1/0.74/1.1	80%/6/0.744/1.1
Alpha variant compatible, Ct<30	Ct≥30	64%/19.3/0.672/1.1	66%/25.5/0.624/1.5	62%/21/0.651/1.2	62%/20.6/0.655/1.1
Delta variant compatible, Ct<30	Wild type, Ct<30	75%/6.4/0.757/1.1	78%/8.5/0.715/1.5	75%/6.5/0.754/1.1	76%/6.4/0.757/1.1
Not yet vaccinated 75%/4.4/0.731/1.1 77%/5.6/0.684/1.4 74%/4.6/0.717/1.1 74%/4.5/0.722/1.1 ≥21 days from 1st vaccine, <0 days from 2nd vaccine 80%/16.5/0.741/1.2 84%/19.5/0.718/1.5 79%/16.9/0.733/1.2 79%/16.5/0.735/1.2 ≥14 days from 2nd vaccine 83%/8.4/0.729/1.2 87%/9.7/0.707/1.4 83%/8.4/0.73/1.2 83%/8.3/0.732/1.1 2-5y 68%/19.6/0.515/1 71%/20.2/0.505/1.1 68%/20.2/0.505/1 63%/10.2/0.58/1.1 6-10y 60%/9.6/0.59/1 65%/11.8/0.54/1.4 63%/10.4/0.575/1.1 63%/10.2/0.58/1.1 11-15y 70%/4.2/0.681/1 76%/5.4/0.63/1.4 70%/4.6/0.658/1.1 71%/4.6/0.663/1.1 16-44y 78%/3.8/0.745/1.1 81%/5.2/0.685/1.5 77%/4.1/0.73/1.1 77%/4.1/0.731/1.1 45-64y 79%/4.2/0.76/1.1 81%/5.4/0.714/1.5 77%/4.4/0.747/1.1 78%/4.3/0.752/1.1 65y+ 73%/8.2/0.711/1.2 74%/9.2/0.693/1.4 71%/8.1/0.62/1.2 46%/41.4/0.627/1.2 164p 79%/4.8/0.725/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 165y+ 73%/8.2/0.711/1.2 74%/9.2/0.693/1.4 71%/8.1/0.62/1.2 46	Alpha variant compatible, Ct<30	81%/7.2/0.754/1.1	84%/9.3/0.712/1.5	80%/7.7/0.74/1.2	81%/7.5/0.747/1.2
≥21 days from 1st vaccine, <0 days from 2nd vaccine	Delta variant compatible, Ct<30	84%/6.6/0.719/1.1	89%/7.9/0.683/1.4	84%/6.8/0.714/1.1	85%/6.8/0.716/1.1
≥14 days from 2nd vaccine 83%/8.4/0.729/1.2 87%/9.7/0.707/1.4 83%/8.4/0.73/1.2 83%/8.3/0.732/1.1 2-5y 68%/19.6/0.515/1 71%/20.2/0.505/1.1 68%/20.2/0.505/1 70%/19.9/0.51/1.1 6-10y 60%/9.6/0.59/1 65%/11.8/0.54/1.4 63%/10.4/0.575/1.1 63%/10.2/0.58/1.1 11-15y 70%/4.2/0.681/1 76%/5.4/0.63/1.4 70%/4.6/0.658/1.1 71%/4.6/0.663/1.1 16-44y 78%/3.8/0.745/1.1 81%/5.2/0.685/1.5 77%/4.1/0.73/1.1 77%/4.1/0.731/1.1 45-64y 79%/4.2/0.76/1.1 81%/5.2/0.693/1.4 71%/8.1/0.707/1.2 71%/7.8/0.715/1.1 65y+ 73%/8.2/0.711/1.2 74%/9.2/0.693/1.4 71%/8.1/0.707/1.2 71%/7.8/0.715/1.1 26Apr2020-30Aug2020 48%/39.8/0.638/1.2 53%/52.2/0.615/1.7 45%/43.1/0.62/1.2 46%/41.4/0.627/1.2 17Nov2020-28Feb2021 70%/4.8/0.725/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	Not yet vaccinated	75%/4.4/0.731/1.1	77%/5.6/0.684/1.4	74%/4.6/0.717/1.1	74%/4.5/0.722/1.1
2-5y68%/19.6/0.515/171%/20.2/0.505/1.168%/20.2/0.505/170%/19.9/0.51/1.16-10y60%/9.6/0.59/165%/11.8/0.54/1.463%/10.4/0.575/1.163%/10.2/0.58/1.111-15y70%/4.2/0.681/176%/5.4/0.63/1.470%/4.6/0.658/1.171%/4.6/0.663/1.116-44y78%/3.8/0.745/1.181%/5.2/0.685/1.577%/4.1/0.73/1.177%/4.1/0.73/1.145-64y79%/4.2/0.76/1.181%/5.4/0.714/1.577%/4.4/0.747/1.178%/4.3/0.752/1.165y+73%/8.2/0.711/1.274%/9.2/0.693/1.471%/8.1/0.707/1.271%/7.8/0.715/1.126Apr2020-30Aug202048%/39.8/0.638/1.253%/52.2/0.615/1.745%/43.1/0.62/1.246%/41.4/0.627/1.21Sep2020-16Nov202070%/4.8/0.725/1.172%/6.3/0.683/1.469%/4.9/0.72/1.170%/4.9/0.723/1.11Mar2021-16May202176%/3.4/0.737/1.178%/4.2/0.69/1.474%/3.6/0.718/1.275%/3.5/0.725/1.11Mar2021-16May202178%/18.2/0.724/1.181%/23.1/0.683/1.578%/19.1/0.714/1.277%/19/0.714/1.2	≥21 days from 1st vaccine, <0 days from 2nd vaccine	80%/16.5/0.741/1.2	84%/19.5/0.718/1.5	79%/16.9/0.733/1.2	79%/16.5/0.735/1.2
6-10y60%/9.6/0.59/165%/11.8/0.54/1.463%/10.4/0.575/1.163%/10.2/0.58/1.111-15y70%/4.2/0.681/176%/5.4/0.63/1.470%/4.6/0.658/1.171%/4.6/0.663/1.116-44y78%/3.8/0.745/1.181%/5.2/0.685/1.577%/4.1/0.73/1.177%/4.1/0.731/1.145-64y79%/4.2/0.76/1.181%/5.4/0.714/1.577%/4.4/0.747/1.178%/4.3/0.752/1.165y+73%/8.2/0.711/1.274%/9.2/0.693/1.471%/8.1/0.707/1.271%/7.8/0.715/1.126Apr2020-30Aug202048%/39.8/0.638/1.253%/52.2/0.615/1.745%/43.1/0.62/1.246%/41.4/0.627/1.21Sep2020-16Nov202070%/4.8/0.725/1.172%/6.3/0.683/1.469%/4.9/0.72/1.170%/4.9/0.723/1.117Nov2020-28Feb202176%/3.4/0.737/1.178%/4.2/0.69/1.474%/3.6/0.718/1.275%/3.5/0.725/1.11Mar2021-16May202178%/18.2/0.724/1.181%/23.1/0.683/1.578%/19.1/0.714/1.277%/19/0.714/1.2	≥14 days from 2nd vaccine	83%/8.4/0.729/1.2	87%/9.7/0.707/1.4	83%/8.4/0.73/1.2	83%/8.3/0.732/1.1
11-15y 70%/4.2/0.681/1 76%/5.4/0.63/1.4 70%/4.6/0.658/1.1 71%/4.6/0.663/1.1 16-44y 78%/3.8/0.745/1.1 81%/5.2/0.685/1.5 77%/4.1/0.73/1.1 77%/4.1/0.731/1.1 45-64y 79%/4.2/0.76/1.1 81%/5.4/0.69/1.4 71%/4.6/0.662/1.2 78%/4.3/0.752/1.1 65y+ 73%/8.2/0.711/1.2 74%/9.2/0.693/1.4 71%/4.1/0.707/1.2 71%/7.8/0.715/1.1 26Apr2020-30Aug2020 48%/39.8/0.638/1.2 53%/52.2/0.615/1.7 45%/43.1/0.62/1.2 46%/41.4/0.627/1.2 18pp2020-16Nov2020 70%/4.8/0.725/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 17Nov2020-28Feb2021 76%/3.4/0.737/1.1 78%/4.2/0.69/1.4 74%/3.6/0.718/1.2 75%/3.5/0.725/1.1 1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	2-5y	68%/19.6/0.515/1	71%/20.2/0.505/1.1	68%/20.2/0.505/1	70%/19.9/0.51/1.1
16-44y 78%/3.8/0.745/1.1 81%/5.2/0.685/1.5 77%/4.1/0.73/1.1 77%/4.1/0.731/1.1 45-64y 79%/4.2/0.76/1.1 81%/5.4/0.714/1.5 77%/4.4/0.747/1.1 78%/4.3/0.752/1.1 65y+ 73%/8.2/0.711/1.2 74%/9.2/0.693/1.4 71%/8.1/0.707/1.2 71%/7.8/0.715/1.1 26Apr2020-30Aug2020 48%/39.8/0.638/1.2 53%/52.2/0.615/1.7 45%/43.1/0.62/1.2 46%/41.4/0.627/1.2 17Nov2020-28Feb2021 76%/3.4/0.737/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	6-10y	60%/9.6/0.59/1	65%/11.8/0.54/1.4	63%/10.4/0.575/1.1	63%/10.2/0.58/1.1
45-64y 79%/4.2/0.76/1.1 81%/5.4/0.714/1.5 77%/4.4/0.747/1.1 78%/4.3/0.752/1.1 65y+ 73%/8.2/0.711/1.2 74%/9.2/0.693/1.4 71%/8.1/0.707/1.2 71%/7.8/0.715/1.1 26Apr2020-30Aug2020 48%/39.8/0.638/1.2 53%/52.2/0.615/1.7 45%/43.1/0.62/1.2 46%/41.4/0.627/1.2 117Nov2020-28Feb2021 70%/4.8/0.725/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 117Nov2020-28Feb2021 76%/3.4/0.737/1.1 78%/4.2/0.69/1.4 74%/3.6/0.718/1.2 75%/3.5/0.725/1.1 110Nar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	11-15y	70%/4.2/0.681/1	76%/5.4/0.63/1.4	70%/4.6/0.658/1.1	71%/4.6/0.663/1.1
65y+ 73%/8.2/0.711/1.2 74%/9.2/0.693/1.4 71%/8.1/0.707/1.2 71%/7.8/0.715/1.1 26Apr2020-30Aug2020 48%/39.8/0.638/1.2 53%/52.2/0.615/1.7 45%/43.1/0.62/1.2 46%/41.4/0.627/1.2 1Sep2020-16Nov2020 70%/4.8/0.725/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 17Nov2020-28Feb2021 76%/3.4/0.737/1.1 78%/4.2/0.69/1.4 74%/3.6/0.718/1.2 75%/3.5/0.725/1.1 1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	16-44y	78%/3.8/0.745/1.1	81%/5.2/0.685/1.5	77%/4.1/0.73/1.1	77%/4.1/0.731/1.1
26Apr2020-30Aug2020 48%/39.8/0.638/1.2 53%/52.2/0.615/1.7 45%/43.1/0.62/1.2 46%/41.4/0.627/1.2 1Sep2020-16Nov2020 70%/4.8/0.725/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 17Nov2020-28Feb2021 76%/3.4/0.737/1.1 78%/4.2/0.69/1.4 74%/3.6/0.718/1.2 75%/3.5/0.725/1.1 1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	45-64y	79%/4.2/0.76/1.1	81%/5.4/0.714/1.5	77%/4.4/0.747/1.1	78%/4.3/0.752/1.1
1Sep2020-16Nov2020 70%/4.8/0.725/1.1 72%/6.3/0.683/1.4 69%/4.9/0.72/1.1 70%/4.9/0.723/1.1 17Nov2020-28Feb2021 76%/3.4/0.737/1.1 78%/4.2/0.69/1.4 74%/3.6/0.718/1.2 75%/3.5/0.725/1.1 1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	65y+	73%/8.2/0.711/1.2	74%/9.2/0.693/1.4	71%/8.1/0.707/1.2	71%/7.8/0.715/1.1
17Nov2020-28Feb2021 76%/3.4/0.737/1.1 78%/4.2/0.69/1.4 74%/3.6/0.718/1.2 75%/3.5/0.725/1.1 1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	26Apr2020-30Aug2020	48%/39.8/0.638/1.2	53%/52.2/0.615/1.7	45%/43.1/0.62/1.2	46%/41.4/0.627/1.2
1Mar2021-16May2021 78%/18.2/0.724/1.1 81%/23.1/0.683/1.5 78%/19.1/0.714/1.2 77%/19/0.714/1.2	1Sep2020-16Nov2020	70%/4.8/0.725/1.1	72%/6.3/0.683/1.4	69%/4.9/0.72/1.1	70%/4.9/0.723/1.1
	17Nov2020-28Feb2021	76%/3.4/0.737/1.1	78%/4.2/0.69/1.4	74%/3.6/0.718/1.2	75%/3.5/0.725/1.1
17May2021-17Jul2021 83%/5 5/0 716/1 1 88%/6 5/0 677/1 4 83%/5 6/0 71/1 1 84%/5 6/0 711/1 1	1Mar2021-16May2021	78%/18.2/0.724/1.1	81%/23.1/0.683/1.5	78%/19.1/0.714/1.2	77%/19/0.714/1.2
	17May2021-17Jul2021	83%/5.5/0.716/1.1	88%/6.5/0.677/1.4	83%/5.6/0.71/1.1	84%/5.6/0.711/1.1

8 Table S6 Number of visits and number of positive tests contributing to the analysis of symptoms reported in positive episodes (N=27,869)

	Number within 35 days, including visit of index positive								
	1	2	3	4	5 -	6+			
Number of visits	8124	13929	2672	1856	1192	96			
	(29%)	(50%)	(10%)	(7%)	(4%)	(0.3%)			
Number of positives	23303	3429	843	224	43				
	(84%)	(12%)	(3%)	(0.8%)	(0.2%)				

Table S7 Summary of number of symptoms among positive episodes present at index positive and ever present at any future visits within [0,35]

days of the index positive, including at visits with negative or missing results (both absent, both present, absent then present, present then absent
for each symptom).

Symptom n(%)	Absent at both index positive and all future visits within 35 days	Absent at index positive, present at at least one subsequent visit	Present at index positive, absent at all future visits within 35 days	Present at both index positive and at least one subsequent visit
		All episode		
any evidence of	9476 (49%)	2880 (15%)	4602 (24%)	2283 (12%)
symptoms	14260 (720)		2027 (15%)	
fatigue weakness	14369 (73%)	1667 (8%)	3027 (15%)	642 (3%)
headache	14731 (75%)	1347 (7%)	3084 (16%)	543 (3%)
cough	14570 (74%)	1262 (6%)	3143 (16%)	730 (4%)
loss of taste	16474 (84%)	1113 (6%)	1802 (9%)	316 (2%)
loss of smell	16579 (84%)	1080 (5%)	1710 (9%)	336 (2%)
muscle ache myalgia	15875 (81%)	1077 (5%)	2395 (12%)	358 (2%)
sore throat	16370 (83%)	887 (5%)	2138 (11%)	310 (2%)
shortness of breath	17318 (88%)	887 (5%)	1248 (6%)	252 (1%)
fever	16690 (85%)	678 (3%)	2100 (11%)	237 (1%)
nausea vomiting	18135 (92%)	496 (3%)	966 (5%)	108 (1%)
diarrhoea	18464 (94%)	412 (2%)	764 (4%)	65 (0%)
abdominal pain	18552 (94%)	376 (2%)	718 (4%)	59 (0%)
	Restricting to epi	sodes with at least 3 visits withi	n 35 days, including the index pos	itive
any evidence of				
symptoms	2132 (39%)	1759 (32%)	486 (9%)	1131 (21%)
fatigue weakness	4009 (69%)	1044 (18%)	395 (7%)	341 (6%)
headache	4120 (71%)	914 (16%)	425 (7%)	330 (6%)
cough	4160 (72%)	819 (14%)	392 (7%)	418 (7%)
loss of taste	4591 (79%)	760 (13%)	246 (4%)	192 (3%)
muscle ache myalgia	4488 (78%)	731 (13%)	348 (6%)	222 (4%)
loss of smell	4660 (80%)	714 (12%)	228 (4%)	187 (3%)
sore throat	4641 (80%)	621 (11%)	316 (5%)	211 (4%)
shortness of breath	4950 (86%)	554 (10%)	158 (3%)	127 (2%)
fever	4826 (83%)	488 (8%)	305 (5%)	170 (3%)
nausea vomiting	5247 (91%)	335 (6%)	131 (2%)	76 (1%)
diarrhoea	5371 (93%)	261 (5%)	112 (2%)	45 (1%)
abdominal pain	5416 (94%)	227 (4%)	106 (2%)	40 (1%)

Note: symptoms are ordered from highest to lowest percentage of positive episodes where the symptom was absent at index positive, but present at at least one subsequent visit in the next 35 days